Skip to main content
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Home
Home

Advanced Search

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses

New Research In

Physical Sciences

Featured Portals

  • Physics
  • Chemistry
  • Sustainability Science

Articles by Topic

  • Applied Mathematics
  • Applied Physical Sciences
  • Astronomy
  • Computer Sciences
  • Earth, Atmospheric, and Planetary Sciences
  • Engineering
  • Environmental Sciences
  • Mathematics
  • Statistics

Social Sciences

Featured Portals

  • Anthropology
  • Sustainability Science

Articles by Topic

  • Economic Sciences
  • Environmental Sciences
  • Political Sciences
  • Psychological and Cognitive Sciences
  • Social Sciences

Biological Sciences

Featured Portals

  • Sustainability Science

Articles by Topic

  • Agricultural Sciences
  • Anthropology
  • Applied Biological Sciences
  • Biochemistry
  • Biophysics and Computational Biology
  • Cell Biology
  • Developmental Biology
  • Ecology
  • Environmental Sciences
  • Evolution
  • Genetics
  • Immunology and Inflammation
  • Medical Sciences
  • Microbiology
  • Neuroscience
  • Pharmacology
  • Physiology
  • Plant Biology
  • Population Biology
  • Psychological and Cognitive Sciences
  • Sustainability Science
  • Systems Biology
Research Article

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

Jeffrey A. Engelman, Pasi A. Jänne, Craig Mermel, Joseph Pearlberg, Toru Mukohara, Christina Fleet, Karen Cichowski, Bruce E. Johnson, and Lewis C. Cantley
PNAS March 8, 2005 102 (10) 3788-3793; https://doi.org/10.1073/pnas.0409773102
Jeffrey A. Engelman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pasi A. Jänne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig Mermel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Pearlberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toru Mukohara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina Fleet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Cichowski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce E. Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lewis C. Cantley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  1. Contributed by Lewis C. Cantley, December 27, 2004

  • Article
  • Figures & SI
  • Info & Metrics
  • PDF
Loading

Online Impact

 

Article Information

vol. 102 no. 10 3788-3793
DOI: 
https://doi.org/10.1073/pnas.0409773102
PubMed: 
15731348

Published By: 
National Academy of Sciences
Print ISSN: 
0027-8424
Online ISSN: 
1091-6490
History: 
  • Published in issue March 8, 2005.
  • Published first February 24, 2005.

Copyright & Usage: 
Copyright © 2005, The National Academy of Sciences

Author Information

  1. Jeffrey A. Engelman * , † , ‡,
  2. Pasi A. Jänne ‡,
  3. Craig Mermel * , †,
  4. Joseph Pearlberg ‡,
  5. Toru Mukohara ‡,
  6. Christina Fleet §,
  7. Karen Cichowski §,
  8. Bruce E. Johnson ‡, and
  9. Lewis C. Cantley * , † , ¶
  1. *Department of Systems Biology, Harvard Medical School, Boston, MA 02115; †Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02215; ‡Department of Medical Oncology, Dana–Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115; and §Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115
  1. Contributed by Lewis C. Cantley, December 27, 2004

Footnotes

  • ↵ ¶ To whom correspondence should be addressed at: Harvard Institutes of Medicine, 77 Avenue Louis Pasteur, Room 1022, Boston, MA 02115. E-mail: lewis_cantley{at}hms.harvard.edu.

  • Author contributions: J.A.E., P.A.J., and L.C.C. designed research; J.A.E., C.M., T.M., and C.F. performed research; J.A.E., P.A.J., J.P., K.C. and B.E.J. contributed new reagents/analytic tools; J.A.E., P.A.J., B.E.J., and L.C.C. analyzed data; and J.A.E. and L.C.C. wrote the paper.

  • Abbreviations: EGFR, EGF receptor; NSCLC, non-small cell lung cancer; PI3K, phosphoinositide 3-kinase; shRNA, short hairpin RNA; TKI, tyrosine kinase inhibitor; IPs, immunoprecipitates; PTyr, phosphotyrosine.

  • Copyright © 2005, The National Academy of Sciences

Cited By...

  • 407 Citations
  • 383 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
    Jeffrey A. Engelman, Ji Luo, Lewis C. Cantley
    Nature Reviews Genetics 2006 7 8
  • Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
    L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman
    Science Translational Medicine 2011 3 75
  • Epidermal growth factor receptor mutations in lung cancer
    Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman, Daniel A. Haber
    Nature Reviews Cancer 2007 7 3
  • Targeting the phosphoinositide 3-kinase pathway in cancer
    Pixu Liu, Hailing Cheng, Thomas M. Roberts, Jean J. Zhao
    Nature Reviews Drug Discovery 2009 8 8
  • Targeting PI3K signalling in cancer: opportunities, challenges and limitations
    Jeffrey A. Engelman
    Nature Reviews Cancer 2009 9 8
  • Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
    Klarisa Rikova, Ailan Guo, Qingfu Zeng, Anthony Possemato, Jian Yu, Herbert Haack, Julie Nardone, Kimberly Lee, Cynthia Reeves, Yu Li, Yerong Hu, Zhiping Tan, Matthew Stokes, Laura Sullivan, Jeffrey Mitchell, Randy Wetzel, Joan MacNeill, Jian Min Ren, Jin Yuan, Corey E. Bakalarski, Judit Villen, Jon M. Kornhauser, Bradley Smith, Daiqiang Li, Xinmin Zhou, Steven P. Gygi, Ting-Lei Gu, Roberto D. Polakiewicz, John Rush, Michael J. Comb
    Cell 2007 131 6
  • Ras, PI(3)K and mTOR signalling controls tumour cell growth
    Reuben J. Shaw, Lewis C. Cantley
    Nature 2006 441 7092
  • EGF–ERBB signalling: towards the systems level
    Ami Citri, Yosef Yarden
    Nature Reviews Molecular Cell Biology 2006 7 7
  • PI3K pathway alterations in cancer: variations on a theme
    T L Yuan, L C Cantley
    Oncogene 2008 27 41
  • MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
    J. Bean, C. Brennan, J.-Y. Shih, G. Riely, A. Viale, L. Wang, D. Chitale, N. Motoi, J. Szoke, S. Broderick, M. Balak, W.-C. Chang, C.-J. Yu, A. Gazdar, H. Pass, V. Rusch, W. Gerald, S.-F. Huang, P.-C. Yang, V. Miller, M. Ladanyi, C.-H. Yang, W. Pao
    Proceedings of the National Academy of Sciences 2007 104 52
  • Epidermal growth factor receptor (EGFR) signaling in cancer
    Nicola Normanno, Antonella De Luca, Caterina Bianco, Luigi Strizzi, Mario Mancino, Monica R. Maiello, Adele Carotenuto, Gianfranco De Feo, Francesco Caponigro, David S. Salomon
    Gene 2006 366 1
  • ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
    Kristin Bergethon, Alice T. Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M. Lovly, Nerina T. McDonald, Pierre P. Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang, Eugene J. Mark, Julie M. Batten, Haiquan Chen, Keith D. Wilner, Eunice L. Kwak, Jeffrey W. Clark, David P. Carbone, Hongbin Ji, Jeffrey A. Engelman, Mari Mino-Kenudson, William Pao, A. John Iafrate
    Journal of Clinical Oncology 2012 30 8
  • BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    D Li, L Ambrogio, T Shimamura, S Kubo, M Takahashi, L R Chirieac, R F Padera, G I Shapiro, A Baum, F Himmelsbach, W J Rettig, M Meyerson, F Solca, H Greulich, K-K Wong
    Oncogene 2008 27 34
  • Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
    José Baselga, Sandra M. Swain
    Nature Reviews Cancer 2009 9 7
  • Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
    R. Katayama, A. T. Shaw, T. M. Khan, M. Mino-Kenudson, B. J. Solomon, B. Halmos, N. A. Jessop, J. C. Wain, A. T. Yeo, C. Benes, L. Drew, J. C. Saeh, K. Crosby, L. V. Sequist, A. J. Iafrate, J. A. Engelman
    Science Translational Medicine 2012 4 120
  • Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
    Alexa B. Turke, Kreshnik Zejnullahu, Yi-Long Wu, Youngchul Song, Dora Dias-Santagata, Eugene Lifshits, Luca Toschi, Andrew Rogers, Tony Mok, Lecia Sequist, Neal I. Lindeman, Carly Murphy, Sara Akhavanfard, Beow Y. Yeap, Yun Xiao, Marzia Capelletti, A. John Iafrate, Charles Lee, James G. Christensen, Jeffrey A. Engelman, Pasi A. Jänne
    Cancer Cell 2010 17 1
  • Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
    Cai-Hong Yun, Titus J. Boggon, Yiqun Li, Michele S. Woo, Heidi Greulich, Matthew Meyerson, Michael J. Eck
    Cancer Cell 2007 11 3
  • ErbB receptors and signaling pathways in cancer
    Nancy E Hynes, Gwen MacDonald
    Current Opinion in Cell Biology 2009 21 2
  • ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
    Carlos L. Arteaga, Jeffrey A. Engelman
    Cancer Cell 2014 25 3
  • Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non–Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition
    Stuart Thomson, Elizabeth Buck, Filippo Petti, Graeme Griffin, Eric Brown, Nishal Ramnarine, Kenneth K. Iwata, Neil Gibson, John D. Haley
    Cancer Research 2005 65 20
  • Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer: Fig. 1.
    Jeffrey A. Engelman, Pasi A. Jänne
    Clinical Cancer Research 2008 14 10
  • Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
    Seiji Yano, Wei Wang, Qi Li, Kunio Matsumoto, Haruko Sakurama, Takahiro Nakamura, Hirokazu Ogino, Soji Kakiuchi, Masaki Hanibuchi, Yasuhiko Nishioka, Hisanori Uehara, Tetsuya Mitsudomi, Yasushi Yatabe, Toshikazu Nakamura, Saburo Sone
    Cancer Research 2008 68 22
  • Understanding resistance to EGFR inhibitors—impact on future treatment strategies
    Deric L. Wheeler, Emily F. Dunn, Paul M. Harari
    Nature Reviews Clinical Oncology 2010 7 9
  • Epidermal Growth Factor Receptor Biology in Head and Neck Cancer
    Shailaja Kalyankrishna, Jennifer R. Grandis
    Journal of Clinical Oncology 2006 24 17
  • HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
    Ken Takezawa, Valentina Pirazzoli, Maria E. Arcila, Caroline A. Nebhan, Xiaoling Song, Elisa de Stanchina, Kadoaki Ohashi, Yelena Y. Janjigian, Paula J. Spitzler, Mary Ann Melnick, Greg J. Riely, Mark G. Kris, Vincent A. Miller, Marc Ladanyi, Katerina Politi, William Pao
    Cancer Discovery 2012 2 10
  • Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients
    Robert L. Yauch, Thomas Januario, David A. Eberhard, Guy Cavet, Wenjing Zhu, Ling Fu, Thinh Q. Pham, Robert Soriano, Jeremy Stinson, Somasekar Seshagiri, Zora Modrusan, Chin-Yu Lin, Vincent O'Neill, Lukas C. Amler
    Clinical Cancer Research 2005 11 24
  • Genetic Heterogeneity of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cell Lines Revealed by a Rapid and Sensitive Detection System, the Peptide Nucleic Acid-Locked Nucleic Acid PCR Clamp
    Yoshiaki Nagai, Hitoshi Miyazawa, Huqun, Tomoaki Tanaka, Kiyoshi Udagawa, Motoyasu Kato, Shunichiro Fukuyama, Akemi Yokote, Kunihiko Kobayashi, Minoru Kanazawa, Koichi Hagiwara
    Cancer Research 2005 65 16
  • Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell Lines
    Samir E. Witta, Robert M. Gemmill, Fred R. Hirsch, Christopher D. Coldren, Karla Hedman, Larisa Ravdel, Barbara Helfrich, Rafal Dziadziuszko, Daniel C. Chan, Michio Sugita, Zeng Chan, Anna Baron, Wilbur Franklin, Harry A. Drabkin, Luc Girard, Adi F. Gazdar, John D. Minna, Paul A. Bunn
    Cancer Research 2006 66 2
  • Signaling networks assembled by oncogenic EGFR and c-Met
    A. Guo, J. Villen, J. Kornhauser, K. A. Lee, M. P. Stokes, K. Rikova, A. Possemato, J. Nardone, G. Innocenti, R. Wetzel, Y. Wang, J. MacNeill, J. Mitchell, S. P. Gygi, J. Rush, R. D. Polakiewicz, M. J. Comb
    Proceedings of the National Academy of Sciences 2008 105 2
  • Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
    K. Yonesaka, K. Zejnullahu, I. Okamoto, T. Satoh, F. Cappuzzo, J. Souglakos, D. Ercan, A. Rogers, M. Roncalli, M. Takeda, Y. Fujisaka, J. Philips, T. Shimizu, O. Maenishi, Y. Cho, J. Sun, A. Destro, K. Taira, K. Takeda, T. Okabe, J. Swanson, H. Itoh, M. Takada, E. Lifshits, K. Okuno, J. A. Engelman, R. A. Shivdasani, K. Nishio, M. Fukuoka, M. Varella-Garcia, K. Nakagawa, P. A. Janne
    Science Translational Medicine 2011 3 99
  • Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells
    Steven J. Isakoff, Jeffrey A. Engelman, Hanna Y. Irie, Ji Luo, Saskia M. Brachmann, Rachel V. Pearline, Lewis C. Cantley, Joan S. Brugge
    Cancer Research 2005 65 23
  • Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network
    Christoph A. Ritter, Marianela Perez-Torres, Cammie Rinehart, Marta Guix, Teresa Dugger, Jeffrey A. Engelman, Carlos L. Arteaga
    Clinical Cancer Research 2007 13 16
  • The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
    Hongbin Ji, Danan Li, Liang Chen, Takeshi Shimamura, Susumu Kobayashi, Kate McNamara, Umar Mahmood, Albert Mitchell, Yangping Sun, Ruqayyah Al-Hashem, Lucian R. Chirieac, Robert Padera, Roderick T. Bronson, William Kim, Pasi A. Jänne, Geoffrey I. Shapiro, Daniel Tenen, Bruce E. Johnson, Ralph Weissleder, Norman E. Sharpless, Kwok-Kin Wong
    Cancer Cell 2006 9 6
  • Regulation of Insulin-Like Growth Factor Signaling by Yap Governs Cardiomyocyte Proliferation and Embryonic Heart Size
    M. Xin, Y. Kim, L. B. Sutherland, X. Qi, J. McAnally, R. J. Schwartz, J. A. Richardson, R. Bassel-Duby, E. N. Olson
    Science Signaling 2011 4 196
  • Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
    Yong Jia, Cai-Hong Yun, Eunyoung Park, Dalia Ercan, Mari Manuia, Jose Juarez, Chunxiao Xu, Kevin Rhee, Ting Chen, Haikuo Zhang, Sangeetha Palakurthi, Jaebong Jang, Gerald Lelais, Michael DiDonato, Badry Bursulaya, Pierre-Yves Michellys, Robert Epple, Thomas H. Marsilje, Matthew McNeill, Wenshuo Lu, Jennifer Harris, Steven Bender, Kwok-Kin Wong, Pasi A. Jänne, Michael J. Eck
    Nature 2016 534 7605
  • Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer
    Monica Kong-Beltran, Somasekar Seshagiri, Jiping Zha, Wenjing Zhu, Kaumudi Bhawe, Nerissa Mendoza, Thomas Holcomb, Kanan Pujara, Jeremy Stinson, Ling Fu, Christophe Severin, Linda Rangell, Ralph Schwall, Lukas Amler, Dineli Wickramasinghe, Robert Yauch
    Cancer Research 2006 66 1
  • Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
    Bin-Bing S. Zhou, Michael Peyton, Biao He, Changnian Liu, Luc Girard, Eian Caudler, Yvonne Lo, Frederic Baribaud, Iwao Mikami, Noemi Reguart, Gengjie Yang, Yanlong Li, Wenqing Yao, Kris Vaddi, Adi F. Gazdar, Steven M. Friedman, David M. Jablons, Robert C. Newton, Jordan S. Fridman, John D. Minna, Peggy A. Scherle
    Cancer Cell 2006 10 1
  • Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology
    Pasi A. Jänne, Jeffrey A. Engelman, Bruce E. Johnson
    Journal of Clinical Oncology 2005 23 14
  • Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib
    Kendall D. Carey, Andrew J. Garton, Maria S. Romero, Jennifer Kahler, Stuart Thomson, Sarajane Ross, Frances Park, John D. Haley, Neil Gibson, Mark X. Sliwkowski
    Cancer Research 2006 66 16
  • Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer
    Gregory J. Riely, Katerina A. Politi, Vincent A. Miller, William Pao
    Clinical Cancer Research 2006 12 24
  • A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
    Gabriele Schaefer, Lauric Haber, Lisa M. Crocker, Steven Shia, Lily Shao, Donald Dowbenko, Klara Totpal, Anne Wong, Chingwei V. Lee, Scott Stawicki, Robyn Clark, Carter Fields, Gail D. Lewis Phillips, Rodney A. Prell, Dimitry M. Danilenko, Yvonne Franke, Jean-Philippe Stephan, Jiyoung Hwang, Yan Wu, Jenny Bostrom, Mark X. Sliwkowski, Germaine Fuh, Charles Eigenbrot
    Cancer Cell 2011 20 4
  • Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer
    Johan Bussink, Albert J van der Kogel, Johannes HAM Kaanders
    The Lancet Oncology 2008 9 3
  • Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations
    Toru Mukohara, Jeffrey A. Engelman, Nasser H. Hanna, Beow Y. Yeap, Susumu Kobayashi, Neal Lindeman, Balázs Halmos, Joseph Pearlberg, Zenta Tsuchihashi, Lewis C. Cantley, Daniel G. Tenen, Bruce E. Johnson, Pasi A. Jänne
    JNCI: Journal of the National Cancer Institute 2005 97 16
  • Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs
    Mayumi Ono, Michihiko Kuwano
    Clinical Cancer Research 2006 12 24
  • Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells
    Bryan C. Fuchs, Tsutomu Fujii, Jon D. Dorfman, Jonathan M. Goodwin, Andrew X. Zhu, Michael Lanuti, Kenneth K. Tanabe
    Cancer Research 2008 68 7
  • An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
    Birgit Schoeberl, Anthony C. Faber, Danan Li, Mei-Chih Liang, Katherine Crosby, Matthew Onsum, Olga Burenkova, Emily Pace, Zandra Walton, Lin Nie, Aaron Fulgham, Youngchul Song, Ulrik B. Nielsen, Jeffrey A. Engelman, Kwok-Kin Wong
    Cancer Research 2010 70 6
  • Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
    M. L. Sos, S. Fischer, R. Ullrich, M. Peifer, J. M. Heuckmann, M. Koker, S. Heynck, I. Stuckrath, J. Weiss, F. Fischer, K. Michel, A. Goel, L. Regales, K. A. Politi, S. Perera, M. Getlik, L. C. Heukamp, S. Ansen, T. Zander, R. Beroukhim, H. Kashkar, K. M. Shokat, W. R. Sellers, D. Rauh, C. Orr, K. P. Hoeflich, L. Friedman, K.-K. Wong, W. Pao, R. K. Thomas
    Proceedings of the National Academy of Sciences 2009 106 43
  • BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors
    Anthony C. Faber, Ryan B. Corcoran, Hiromichi Ebi, Lecia V. Sequist, Belinda A. Waltman, Euiheon Chung, Joao Incio, Subba R. Digumarthy, Sarah F. Pollack, Youngchul Song, Alona Muzikansky, Eugene Lifshits, Sylvie Roberge, Erik J. Coffman, Cyril H. Benes, Henry L. Gómez, José Baselga, Carlos L. Arteaga, Miguel N. Rivera, Dora Dias-Santagata, Rakesh K. Jain, Jeffrey A. Engelman
    Cancer Discovery 2011 1 4
  • EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
    Dalia Ercan, Hwan Geun Choi, Cai-Hong Yun, Marzia Capelletti, Ting Xie, Michael J. Eck, Nathanael S. Gray, Pasi A. Jänne
    Clinical Cancer Research 2015 21 17
  • Epidermal Growth Factor Receptors Harboring Kinase Domain Mutations Associate with the Heat Shock Protein 90 Chaperone and Are Destabilized following Exposure to Geldanamycins
    Takeshi Shimamura, April M. Lowell, Jeffrey A. Engelman, Geoffrey I. Shapiro
    Cancer Research 2005 65 14
  • Targeting HER proteins in cancer therapy and the role of the non-target HER3
    A C Hsieh, M M Moasser
    British Journal of Cancer 2007 97 4
  • Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells
    Kaisa Erjala, Maria Sundvall, Teemu T. Junttila, Na Zhang, Mika Savisalo, Pekka Mali, Jarmo Kulmala, Jaakko Pulkkinen, Reidar Grenman, Klaus Elenius
    Clinical Cancer Research 2006 12 13
  • Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
    George N. Naumov, Monique B. Nilsson, Tina Cascone, Alexandra Briggs, Oddbjorn Straume, Lars A. Akslen, Eugene Lifshits, Lauren Averett Byers, Li Xu, Hua-kang Wu, Pasi Jänne, Susumu Kobayashi, Balazs Halmos, Daniel Tenen, Xi M. Tang, Jeffrey Engelman, Beow Yeap, Judah Folkman, Bruce E. Johnson, John V. Heymach
    Clinical Cancer Research 2009 15 10
  • A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening
    Pasi A. Jänne, Ana M. Borras, Yanan Kuang, Andrew M. Rogers, Victoria A. Joshi, Hema Liyanage, Neal Lindeman, Jeffrey C. Lee, Balazs Halmos, Elizabeth A. Maher, Robert J. Distel, Matthew Meyerson, Bruce E. Johnson
    Clinical Cancer Research 2006 12 3
  • Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
    Dalia Ercan, Chunxiao Xu, Masahiko Yanagita, Calixte S. Monast, Christine A. Pratilas, Joan Montero, Mohit Butaney, Takeshi Shimamura, Lynette Sholl, Elena V. Ivanova, Madhavi Tadi, Andrew Rogers, Claire Repellin, Marzia Capelletti, Ophélia Maertens, Eva M. Goetz, Anthony Letai, Levi A. Garraway, Matthew J. Lazzara, Neal Rosen, Nathanael S. Gray, Kwok-Kin Wong, Pasi A. Jänne
    Cancer Discovery 2012 2 10
  • Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors
    Elizabeth Buck, Alexandra Eyzaguirre, Eric Brown, Filippo Petti, Siobhan McCormack, John D. Haley, Kenneth K. Iwata, Neil W. Gibson, Graeme Griffin
    Molecular Cancer Therapeutics 2006 5 11
  • MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
    Alexa B. Turke, Youngchul Song, Carlotta Costa, Rebecca Cook, Carlos L. Arteaga, John M. Asara, Jeffrey A. Engelman
    Cancer Research 2012 72 13
  • Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
    D Ercan, K Zejnullahu, K Yonesaka, Y Xiao, M Capelletti, A Rogers, E Lifshits, A Brown, C Lee, J G Christensen, D J Kwiatkowski, J A Engelman, P A Jänne
    Oncogene 2010 29 16
  • Mechanisms of Disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer
    Yungan Tao, Valentina Pinzi, Jean Bourhis, Eric Deutsch
    Nature Clinical Practice Oncology 2007 4 10
  • Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
    A Burchert, Y Wang, D Cai, N von Bubnoff, P Paschka, S Müller-Brüsselbach, O G Ottmann, J Duyster, A Hochhaus, A Neubauer
    Leukemia 2005 19 10
  • Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy
    Danan Li, Takeshi Shimamura, Hongbin Ji, Liang Chen, Henry J. Haringsma, Kate McNamara, Mei-Chih Liang, Samanthi A. Perera, Sara Zaghlul, Christa L. Borgman, Shigeto Kubo, Masaya Takahashi, Yanping Sun, Lucian R. Chirieac, Robert F. Padera, Neal I. Lindeman, Pasi A. Jänne, Roman K. Thomas, Matthew L. Meyerson, Michael J. Eck, Jeffrey A. Engelman, Geoffrey I. Shapiro, Kwok-Kin Wong
    Cancer Cell 2007 12 1
  • Airway PI3K Pathway Activation Is an Early and Reversible Event in Lung Cancer Development
    A. M. Gustafson, R. Soldi, C. Anderlind, M. B. Scholand, J. Qian, X. Zhang, K. Cooper, D. Walker, A. McWilliams, G. Liu, E. Szabo, J. Brody, P. P. Massion, M. E. Lenburg, S. Lam, A. H. Bild, A. Spira
    Science Translational Medicine 2010 2 26
  • The p110  isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation
    J. J. Zhao, H. Cheng, S. Jia, L. Wang, O. V. Gjoerup, A. Mikami, T. M. Roberts
    Proceedings of the National Academy of Sciences 2006 103 44
  • The ERBB3 receptor in cancer and cancer gene therapy
    G Sithanandam, L M Anderson
    Cancer Gene Therapy 2008 15 7
  • High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies
    Hongdo Do, Michael Krypuy, Paul L Mitchell, Stephen B Fox, Alexander Dobrovic
    BMC Cancer 2008 8 1
  • NKX2-1/TITF1/TTF-1-Induced ROR1 Is Required to Sustain EGFR Survival Signaling in Lung Adenocarcinoma
    Tomoya Yamaguchi, Kiyoshi Yanagisawa, Ryoji Sugiyama, Yasuyuki Hosono, Yukako Shimada, Chinatsu Arima, Seiichi Kato, Shuta Tomida, Motoshi Suzuki, Hirotaka Osada, Takashi Takahashi
    Cancer Cell 2012 21 3
  • Non–Small Cell Lung Cancers with Kinase Domain Mutations in the Epidermal Growth Factor Receptor Are Sensitive to Ionizing Radiation
    Amit K. Das, Mitsuo Sato, Michael D. Story, Michael Peyton, Robert Graves, Stella Redpath, Luc Girard, Adi F. Gazdar, Jerry W. Shay, John D. Minna, Chaitanya S. Nirodi
    Cancer Research 2006 66 19
  • Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
    Hiromichi Ebi, Ryan B. Corcoran, Anurag Singh, Zhao Chen, Youngchul Song, Eugene Lifshits, David P. Ryan, Jeffrey A. Meyerhardt, Cyril Benes, Jeffrey Settleman, Kwok-Kin Wong, Lewis C. Cantley, Jeffrey A. Engelman
    Journal of Clinical Investigation 2011 121 11
  • Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
    Helena Linardou, Issa J. Dahabreh, Dimitrios Bafaloukos, Paris Kosmidis, Samuel Murray
    Nature Reviews Clinical Oncology 2009 6 6
  • Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions
    Sharon Barr, Stuart Thomson, Elizabeth Buck, Suzanne Russo, Filippo Petti, Izabela Sujka-Kwok, Alexandra Eyzaguirre, Maryland Rosenfeld-Franklin, Neil W. Gibson, Mark Miglarese, David Epstein, Kenneth K. Iwata, John D. Haley
    Clinical & Experimental Metastasis 2008 25 6
  • Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors
    Helen Su, Claudia Bodenstein, Rebecca A. Dumont, Yann Seimbille, Steven Dubinett, Michael E. Phelps, Harvey Herschman, Johannes Czernin, Wolfgang Weber
    Clinical Cancer Research 2006 12 19
  • From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice
    Aya Jakobovits, Rafael G Amado, Xiaodong Yang, Lorin Roskos, Gisela Schwab
    Nature Biotechnology 2007 25 10
  • Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors
    Jie Qi, Michele A. McTigue, Andrew Rogers, Eugene Lifshits, James G. Christensen, Pasi A. Jänne, Jeffrey A. Engelman
    Cancer Research 2011 71 3
  • Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition
    Elizabeth Buck, Alexandra Eyzaguirre, Sharon Barr, Stuart Thompson, Regina Sennello, David Young, Kenneth K. Iwata, Neil W. Gibson, Pablo Cagnoni, John D. Haley
    Molecular Cancer Therapeutics 2007 6 2
  • Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
    Ritwik Ghosh, Archana Narasanna, Shizhen Emily Wang, Shuying Liu, Anindita Chakrabarty, Justin M. Balko, Ana María González-Angulo, Gordon B. Mills, Elicia Penuel, John Winslow, Jeff Sperinde, Rajiv Dua, Sailaja Pidaparthi, Ali Mukherjee, Kim Leitzel, Wolfgang J. Kostler, Allan Lipton, Michael Bates, Carlos L. Arteaga
    Cancer Research 2011 71 5
  • The Epidermal Growth Factor Receptor: A Role in Repair of Radiation-Induced DNA Damage
    David J. Chen, Chaitanya S. Nirodi
    Clinical Cancer Research 2007 13 22
  • Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non–Small Cell Lung Cancer Cell Line
    Atsuko Ogino, Hiroyuki Kitao, Seiki Hirano, Akiko Uchida, Masamichi Ishiai, Toshiyuki Kozuki, Nagio Takigawa, Minoru Takata, Katsuyuki Kiura, Mitsune Tanimoto
    Cancer Research 2007 67 16
  • HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy
    Marcia R. Campbell, Dhara Amin, Mark M. Moasser
    Clinical Cancer Research 2010 16 5
  • Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer
    Todd W. Miller, Marianela Pérez-Torres, Archana Narasanna, Marta Guix, Olle Stål, Gizeh Pérez-Tenorio, Ana M. Gonzalez-Angulo, Bryan T. Hennessy, Gordon B. Mills, J. Phillip Kennedy, Craig W. Lindsley, Carlos L. Arteaga
    Cancer Research 2009 69 10
  • Transforming Growth Factor β Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab
    Shizhen Emily Wang, Bin Xiang, Marta Guix, Maria Graciela Olivares, Joel Parker, Christine H. Chung, Atanasio Pandiella, Carlos L. Arteaga
    Molecular and Cellular Biology 2008 28 18
  • Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma
    Christèle Desbois-Mouthon, Aurore Baron, Marie-José Blivet-Van Eggelpoël, Laetitia Fartoux, Corinne Venot, Friedhelm Bladt, Chantal Housset, Olivier Rosmorduc
    Clinical Cancer Research 2009 15 17
  • Genomics in Cancer Drug Discovery and Development
    Debashis Sarker, Paul Workman
    2006 96
  • Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance
    Takeshi Shimamura, Danan Li, Hongbin Ji, Henry J. Haringsma, Elizabeth Liniker, Christa L. Borgman, April M. Lowell, Yuko Minami, Kate McNamara, Samanthi A. Perera, Sara Zaghlul, Roman K. Thomas, Heidi Greulich, Susumu Kobayashi, Lucian R. Chirieac, Robert F. Padera, Shigeto Kubo, Masaya Takahashi, Daniel G. Tenen, Matthew Meyerson, Kwok-Kin Wong, Geoffrey I. Shapiro
    Cancer Research 2008 68 14
  • Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Emiliano Calvo, José Baselga
    Journal of Clinical Oncology 2006 24 14
  • Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas
    Eunice L. Kwak, Janusz Jankowski, Sarah P. Thayer, Gregory Y. Lauwers, Brian W. Brannigan, Patricia L. Harris, Ross A. Okimoto, Sara M. Haserlat, David R. Driscoll, David Ferry, Beth Muir, Jeff Settleman, Charles S. Fuchs, Matthew H. Kulke, David P. Ryan, Jeff W. Clark, Dennis C. Sgroi, Daniel A. Haber, Daphne W. Bell
    Clinical Cancer Research 2006 12 14
  • EGFR-mutated lung cancer: a paradigm of molecular oncology
    Zhenfeng Zhang, Amy L. Stiegler, Titus J. Boggon, Susumu Kobayashi, Balazs Halmos
    Oncotarget 2010 1 7
  • High Expression of ErbB Family Members and Their Ligands in Lung Adenocarcinomas That Are Sensitive to Inhibition of Epidermal Growth Factor Receptor
    Nobukazu Fujimoto, Marie Wislez, Jie Zhang, Kentaro Iwanaga, Jennifer Dackor, Amy E. Hanna, Shailaja Kalyankrishna, Dianna D. Cody, Roger E. Price, Mitsuo Sato, Jerry W. Shay, John D. Minna, Michael Peyton, Ximing Tang, Erminia Massarelli, Roy Herbst, David W. Threadgill, Ignacio I. Wistuba, Jonathan M. Kurie
    Cancer Research 2005 65 24
  • Mechanisms of receptor tyrosine kinase activation in cancer
    Zhenfang Du, Christine M. Lovly
    Molecular Cancer 2018 17 1
  • Validating cancer drug targets
    John D. Benson, Ying-Nan P. Chen, Susan A. Cornell-Kennon, Marion Dorsch, Sunkyu Kim, Magdalena Leszczyniecka, William R. Sellers, Christoph Lengauer
    Nature 2006 441 7092
  • A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer
    Emily M. Fox, Todd W. Miller, Justin M. Balko, Maria G. Kuba, Violeta Sánchez, R. Adam Smith, Shuying Liu, Ana María González-Angulo, Gordon B. Mills, Fei Ye, Yu Shyr, H. Charles Manning, Elizabeth Buck, Carlos L. Arteaga
    Cancer Research 2011 71 21
  • Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148
    Amit M. Oza, Elizabeth A. Eisenhauer, Laurie Elit, Jean-Claude Cutz, Akira Sakurada, Ming S. Tsao, Paul J. Hoskins, Jim Biagi, Prafull Ghatage, John Mazurka, Diane Provencher, Naomi Dore, Janet Dancey, Anthony Fyles
    Journal of Clinical Oncology 2008 26 26
  • Somatic Mutations in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor (EGFR) Abrogate EGFR-Mediated Radioprotection in Non–Small Cell Lung Carcinoma
    Amit K. Das, Benjamin P. Chen, Michael D. Story, Mitsuo Sato, John D. Minna, David J. Chen, Chaitanya S. Nirodi
    Cancer Research 2007 67 11
  • Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Pasi A. Jänne, Bruce E. Johnson
    Clinical Cancer Research 2006 12 14
  • The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts
    Nathan T. Ihle, Gillian Paine-Murrieta, Margareta I. Berggren, Amanda Baker, Wendy R. Tate, Peter Wipf, Robert T. Abraham, D. Lynn Kirkpatrick, Garth Powis
    Molecular Cancer Therapeutics 2005 4 9
  • Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells
    Wei-Chien Huang, Yun-Ju Chen, Long-Yuan Li, Ya-Ling Wei, Sheng-Chieh Hsu, Shing-Ling Tsai, Pei-Chun Chiu, Wei-Pang Huang, Ying-Nai Wang, Chung-Hsuan Chen, Wei-Chao Chang, Wen-Chang Chang, Andy Jer-En Chen, Chang-Hai Tsai, Mien-Chie Hung
    Journal of Biological Chemistry 2011 286 23
  • Src-Family Kinases Are Activated in Non-Small Cell Lung Cancer and Promote the Survival of Epidermal Growth Factor Receptor-Dependent Cell Lines
    Jie Zhang, Shailaja Kalyankrishna, Marie Wislez, Nishan Thilaganathan, Babita Saigal, Wei Wei, Long Ma, Ignacio I. Wistuba, Faye M. Johnson, Jonathan M. Kurie
    The American Journal of Pathology 2007 170 1
  • EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
    Kenichi Suda, Ryoichi Onozato, Yasushi Yatabe, Tetsuya Mitsudomi
    Journal of Thoracic Oncology 2009 4 1
  • High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH
    Cathie Garnis, William W. Lockwood, Emily Vucic, Yong Ge, Luc Girard, John D. Minna, Adi F. Gazdar, Stephen Lam, Calum MacAulay, Wan L. Lam
    International Journal of Cancer 2006 118 6
  • Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma
    Federico Rojo, Josep Tabernero, Joan Albanell, Eric Van Cutsem, Atsushi Ohtsu, Toshihiko Doi, Wasaburo Koizumi, Kuniaki Shirao, Hiroya Takiuchi, S. Ramon Cajal, José Baselga
    Journal of Clinical Oncology 2006 24 26
  • Epidermal Growth Factor Receptor Mutations in Patients with Non–Small Cell Lung Cancer
    Bruce E. Johnson, Pasi A. Jänne
    Cancer Research 2005 65 17
  • HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT
    Francesca Bruzzese, Alessandra Leone, Monia Rocco, Carmine Carbone, Geny Piro, Michele Caraglia, Elena Di Gennaro, Alfredo Budillon
    Journal of Cellular Physiology 2011 226 9
  • High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507)
    Yixuan Gong, Evelyn Yao, Ronglai Shen, Aviva Goel, Maria Arcila, Julie Teruya-Feldstein, Maureen F. Zakowski, Stanley Frankel, Martin Peifer, Roman K. Thomas, Marc Ladanyi, William Pao, Mikhail V. Blagosklonny
    PLoS ONE 2009 4 10
  • Mect1-Maml2 Fusion Oncogene Linked to the Aberrant Activation of Cyclic AMP/CREB Regulated Genes
    Amy Coxon, Ester Rozenblum, Yoon-Soo Park, Nina Joshi, Junji Tsurutani, Phillip A. Dennis, Ilan R. Kirsch, Frederic J. Kaye
    Cancer Research 2005 65 16
  • Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines
    Christopher D. Coldren, Barbara A. Helfrich, Samir E. Witta, Michio Sugita, Razvan Lapadat, Chan Zeng, Anna Barón, Wilbur A. Franklin, Fred R. Hirsch, Mark W. Geraci, Paul A. Bunn
    Molecular Cancer Research 2006 4 8
  • The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics
    Dhara N. Amin, Marcia R. Campbell, Mark M. Moasser
    Seminars in Cell & Developmental Biology 2010 21 9
  • Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling
    K Shtiegman, B S Kochupurakkal, Y Zwang, G Pines, A Starr, A Vexler, A Citri, M Katz, S Lavi, Y Ben-Basat, S Benjamin, S Corso, J Gan, R B Yosef, S Giordano, Y Yarden
    Oncogene 2007 26 49
  • Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment
    Reinhard Buettner, Jürgen Wolf, Roman K. Thomas
    Journal of Clinical Oncology 2013 31 15
  • Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer
    Michael J. Eck, Cai-Hong Yun
    Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 2010 1804 3
  • Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer
    H-J Lin, F-C Hsieh, H Song, J Lin
    British Journal of Cancer 2005 93 12
  • Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
    Luis Paz-Ares, Denis Soulières, Ivan Melezínek, Joachim Moecks, Lorenz Keil, Tony Mok, Rafael Rosell, Barbara Klughammer
    Journal of Cellular and Molecular Medicine 2010 14 1-2
  • Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers
    Kimio Yonesaka, Kreshnik Zejnullahu, Neal Lindeman, Alison J. Homes, David M. Jackman, Feng Zhao, Andrew M. Rogers, Bruce E. Johnson, Pasi A. Jänne
    Clinical Cancer Research 2008 14 21
  • Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib
    Christèle Desbois-Mouthon, Wulfran Cacheux, Marie-José Blivet-Van Eggelpoël, Véronique Barbu, Laetitia Fartoux, Raoul Poupon, Chantal Housset, Olivier Rosmorduc
    International Journal of Cancer 2006 119 11
  • Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity
    Elizabeth Buck, Alexandra Eyzaguirre, John D. Haley, Neil W. Gibson, Pablo Cagnoni, Kenneth K. Iwata
    Molecular Cancer Therapeutics 2006 5 8
  • Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt
    Fumiyuki Yamasaki, Mary J. Johansen, Dongwei Zhang, Savitri Krishnamurthy, Edward Felix, Chandra Bartholomeusz, Richard J. Aguilar, Kaoru Kurisu, Gordon B. Mills, Gabriel N. Hortobagyi, Naoto T. Ueno
    Cancer Research 2007 67 12
  • A Neutralizing RNA Aptamer against EGFR Causes Selective Apoptotic Cell Death
    Carla Lucia Esposito, Diana Passaro, Immacolata Longobardo, Gerolama Condorelli, Pina Marotta, Andrea Affuso, Vittorio de Franciscis, Laura Cerchia, Pan-Chyr Yang
    PLoS ONE 2011 6 9
  • Class 1A PI3K regulates vessel integrity during development and tumorigenesis
    T. L. Yuan, H. S. Choi, A. Matsui, C. Benes, E. Lifshits, J. Luo, J. V. Frangioni, L. C. Cantley
    Proceedings of the National Academy of Sciences 2008 105 28
  • KRASmutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach
    Young-Kwang Yoon, Hwang-Phill Kim, Sae-Won Han, Do Youn Oh, Seock-Ah Im, Yung-Jue Bang, Tae-You Kim
    Molecular Carcinogenesis 2010 49 4
  • The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
    Y Minami, T Shimamura, K Shah, T LaFramboise, K A Glatt, E Liniker, C L Borgman, H J Haringsma, W Feng, B A Weir, A M Lowell, J C Lee, J Wolf, G I Shapiro, K-K Wong, M Meyerson, R K Thomas
    Oncogene 2007 26 34
  • PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors
    Ingo K. Mellinghoff, Tim F. Cloughesy, Paul S. Mischel
    Clinical Cancer Research 2007 13 2
  • ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors
    Cheng-Po Huang, Meng-Feng Tsai, Tzu-Hua Chang, Wei-Chien Tang, Su-Yu Chen, Hsiao-Hsuan Lai, Ting-Yu Lin, James Chih-Hsin Yang, Pan-Chyr Yang, Jin-Yuan Shih, Shwu-Bin Lin
    Cancer Letters 2013 328 1
  • CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy
    Rudi Bao, Cheng-Jung Lai, Hui Qu, Dagong Wang, Ling Yin, Brian Zifcak, Ruzanna Atoyan, Jing Wang, Maria Samson, Jeffrey Forrester, Steven DellaRocca, Guang-Xin Xu, Xu Tao, Hai-Xiao Zhai, Xiong Cai, Changgeng Qian
    Clinical Cancer Research 2009 15 12
  • Epidermal Growth Factor Receptor Activation Protects Gastric Epithelial Cells From Helicobacter pylori-Induced Apoptosis
    Fang Yan, Hanwei Cao, Rupesh Chaturvedi, Uma Krishna, Stuart S. Hobbs, Peter J. Dempsey, Richard M. Peek, Timothy L. Cover, M. Kay Washington, Keith T. Wilson, D. Brent Polk
    Gastroenterology 2009 136 4
  • The HER family and cancer: emerging molecular mechanisms and therapeutic targets
    Natalia V. Sergina, Mark M. Moasser
    Trends in Molecular Medicine 2007 13 12
  • Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
    G E Konecny, N Venkatesan, G Yang, J Dering, C Ginther, R Finn, M Rahmeh, M Schoenberg Fejzo, D Toft, S-W Jiang, D J Slamon, K C Podratz
    British Journal of Cancer 2008 98 6
  • EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors
    Kenji Takeuchi, Fumiaki Ito
    FEBS Journal 2010 277 2
  • Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer: Table 1.
    John V. Heymach, Monique Nilsson, George Blumenschein, Vassiliki Papadimitrakopoulou, Roy Herbst
    Clinical Cancer Research 2006 12 14
  • Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
    S Agarwal, C Zerillo, J Kolmakova, J G Christensen, L N Harris, D L Rimm, M P DiGiovanna, D F Stern
    British Journal of Cancer 2009 100 6
  • The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors: Fig. 1.
    Jeffrey A. Engelman, Lewis C. Cantley
    Clinical Cancer Research 2006 12 14
  • Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium
    Daekee Lee, Ming Yu, Eunjung Lee, Hyunok Kim, Yanan Yang, Kyoungmi Kim, Christina Pannicia, Jonathan M. Kurie, David W. Threadgill
    Journal of Clinical Investigation 2009 119 9
  • Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
    Hiroshi Yokouchi, Koichi Yamazaki, Ichiro Kinoshita, Jun Konishi, Hajime Asahina, Noriaki Sukoh, Masao Harada, Kenji Akie, Shigeaki Ogura, Takashi Ishida, Mitsuru Munakata, Hirotoshi Dosaka-Akita, Hiroshi Isobe, Masaharu Nishimura
    BMC Cancer 2007 7 1
  • HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
    F Cappuzzo, L Toschi, I Domenichini, S Bartolini, G L Ceresoli, E Rossi, V Ludovini, A Cancellieri, E Magrini, L Bemis, W A Franklin, L Crino, P A Bunn, F R Hirsch, M Varella-Garcia
    British Journal of Cancer 2005 93 12
  • Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
    Kathryn Tworkoski, Garima Singhal, Sebastian Szpakowski, Christina Ivins Zito, Antonella Bacchiocchi, Viswanathan Muthusamy, Marcus Bosenberg, Michael Krauthammer, Ruth Halaban, David F. Stern
    Molecular Cancer Research 2011 9 6
  • Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
    Vikram Deshpande, Afamefuna Nduaguba, Stephanie M Zimmerman, Sarah M Kehoe, Laura E MacConaill, Gregory Y Lauwers, Cristina Ferrone, Nabeel Bardeesy, Andrew X Zhu, Aram F Hezel
    BMC Cancer 2011 11 1
  • Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations
    P. Littlefield, L. Liu, V. Mysore, Y. Shan, D. E. Shaw, N. Jura
    Science Signaling 2014 7 354
  • Emerging Role of mTOR in the Response to Cancer Therapeutics
    Erika Ilagan, Brendan D. Manning
    Trends in Cancer 2016 2 5
  • Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway
    Rafael Rosell, Miquel Taron, Noemi Reguart, Dolores Isla, Teresa Moran
    Clinical Cancer Research 2006 12 24
  • Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
    Patricia LoRusso, Pasi A. Jänne, Moacyr Oliveira, Naiyer Rizvi, Lisa Malburg, Vicki Keedy, Lorrin Yee, Catherine Copigneaux, Thore Hettmann, Chi-Yuan Wu, Agnes Ang, Abdel-Baset Halim, Robert A. Beckman, Darrin Beaupre, Jordan Berlin
    Clinical Cancer Research 2013 19 11
  • Retracted: Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines
    Shirish M. Gadgeel, Shadan Ali, Philip A. Philip, Antoinette Wozniak, Fazlul H. Sarkar
    Cancer 2009 115 10
  • The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
    Min Yuan, Li-Li Huang, Jian-Hua Chen, Jie Wu, Qing Xu
    Signal Transduction and Targeted Therapy 2019 4 1
  • Epithelial-to-Mesenchymal Transition Rewires the Molecular Path to PI3K-Dependent Proliferation
    Megan B. Salt, Sourav Bandyopadhyay, Frank McCormick
    Cancer Discovery 2014 4 2
  • Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway
    Kazuko Sakai, Hideyuki Yokote, Kimiko Murakami-Murofushi, Tomohide Tamura, Nagahiro Saijo, Kazuto Nishio
    Cancer Science 2007 98 9
  • Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3
    Bo Ling, Gui-Xue Wang, Guang Long, Ju-Hui Qiu, Zhong-Lei Hu
    Journal of Cancer Research and Clinical Oncology 2012 138 8
  • Breast cancer: Current and future endocrine therapies
    Carlo Palmieri, Darren K. Patten, Adam Januszewski, Giorgia Zucchini, Sacha J. Howell
    Molecular and Cellular Endocrinology 2014 382 1
  • Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
    Kirstine Jacobsen, Jordi Bertran-Alamillo, Miguel Angel Molina, Cristina Teixidó, Niki Karachaliou, Martin Haar Pedersen, Josep Castellví, Mónica Garzón, Carles Codony-Servat, Jordi Codony-Servat, Ana Giménez-Capitán, Ana Drozdowskyj, Santiago Viteri, Martin R. Larsen, Ulrik Lassen, Enriqueta Felip, Trever G. Bivona, Henrik J. Ditzel, Rafael Rosell
    Nature Communications 2017 8 1
  • Phosphoinositide 3-Kinase Pathway Activation in Phosphate and Tensin Homolog (PTEN)-deficient Prostate Cancer Cells Is Independent of Receptor Tyrosine Kinases and Mediated by the p110β and p110δ Catalytic Subunits
    Xinnong Jiang, Sen Chen, John M. Asara, Steven P. Balk
    Journal of Biological Chemistry 2010 285 20
  • Recent advances of bispecific antibodies in solid tumors
    Shengnan Yu, Anping Li, Qian Liu, Xun Yuan, Hanxiao Xu, Dechao Jiao, Richard G. Pestell, Xinwei Han, Kongming Wu
    Journal of Hematology & Oncology 2017 10 1
  • Spheroid Culture of Primary Lung Cancer Cells with Neuregulin 1/HER3 Pathway Activation
    Hiroko Endo, Jiro Okami, Hiroaki Okuyama, Toru Kumagai, Junji Uchida, Jumpei Kondo, Tetsuo Takehara, Yasuko Nishizawa, Fumio Imamura, Masahiko Higashiyama, Masahiro Inoue
    Journal of Thoracic Oncology 2013 8 2
  • Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours
    Pasi A. Jänne
    Lung Cancer 2008 60
  • EGFR Signaling Regulates Tumor Cell Migration in Craniopharyngiomas
    Annett Hölsken, Matthias Gebhardt, Michael Buchfelder, Rudolf Fahlbusch, Ingmar Blümcke, Rolf Buslei
    Clinical Cancer Research 2011 17 13
  • HER3 and mutant EGFR meet MET
    Carlos L Arteaga
    Nature Medicine 2007 13 6
  • HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
    Anthony Kong, Véronique Calleja, Pierre Leboucher, Adrian Harris, Peter J. Parker, Banafshé Larijani, Mikhail V. Blagosklonny
    PLoS ONE 2008 3 8
  • The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies
    Jaclyn A. Freudenberg, Qiang Wang, Makoto Katsumata, Jeffrey Drebin, Izumi Nagatomo, Mark I. Greene
    Experimental and Molecular Pathology 2009 87 1
  • Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations
    In Hae Park, Jin Young Kim, Jae In Jung, Ji-Youn Han
    Investigational New Drugs 2010 28 6
  • Target-specific near-IR induced drug release and photothermal therapy with accumulated Au/Ag hollow nanoshells on pulmonary cancer cell membranes
    Mi Suk Noh, Somin Lee, Homan Kang, Jin-Kyoung Yang, Hyunmi Lee, Doyk Hwang, Jong Woo Lee, Sinyoung Jeong, Yoonjeong Jang, Bong-Hyun Jun, Dae Hong Jeong, Seong Keun Kim, Yoon-Sik Lee, Myung-Haing Cho
    Biomaterials 2015 45
  • Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
    Paul A. Bunn, Rafal Dziadziuszko, Marileila Varella-Garcia, Wilbur A. Franklin, Samir E. Witta, Karen Kelly, Fred R. Hirsch
    Clinical Cancer Research 2006 12 12
  • Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis
    Silke Kaulfuβ, Peter Burfeind, Jochen Gaedcke, Jens-Gerd Scharf
    Molecular Cancer Therapeutics 2009 8 4
  • Erlotinib Directly Inhibits HER2 Kinase Activation and Downstream Signaling Events in Intact Cells Lacking Epidermal Growth Factor Receptor Expression
    Gabriele Schaefer, Lihua Shao, Klara Totpal, Robert W. Akita
    Cancer Research 2007 67 3
  • Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines
    Silvia La Monica, Maricla Galetti, Roberta R. Alfieri, Andrea Cavazzoni, Andrea Ardizzoni, Marcello Tiseo, Marzia Capelletti, Matteo Goldoni, Sara Tagliaferri, Antonio Mutti, Claudia Fumarola, Mara Bonelli, Daniele Generali, Pier Giorgio Petronini
    Biochemical Pharmacology 2009 78 5
  • HER Kinase Axis Receptor Dimer Partner Switching Occurs in Response to EGFR Tyrosine Kinase Inhibition despite Failure to Block Cellular Proliferation
    Anjali Jain, Elicia Penuel, Sheldon Mink, Joanna Schmidt, Amanda Hodge, Kristin Favero, Charles Tindell, David B. Agus
    Cancer Research 2010 70 5
  • MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer
    Miao Zhong, Xin Ma, Caijun Sun, Ling Chen
    Chemico-Biological Interactions 2010 184 3
  • A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer
    S.B. Kaye, C.J. Poole, A. Dańska-Bidzińska, L. Gianni, G. Del Conte, V. Gorbunova, E. Novikova, A. Strauss, M. Moczko, V.A. McNally, G. Ross, I. Vergote
    Annals of Oncology 2013 24 1
  • Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules
    N. Kronqvist, M. Malm, L. Gostring, E. Gunneriusson, M. Nilsson, I. Hoiden Guthenberg, L. Gedda, F. Y. Frejd, S. Stahl, J. Lofblom
    Protein Engineering Design and Selection 2011 24 4
  • RNA Interference Against Hepatic Epidermal Growth Factor Receptor Has Suppressive Effects on Liver Regeneration in Rats
    Shirish Paranjpe, William C. Bowen, George C. Tseng, Jian-Hua Luo, Anne Orr, George K. Michalopoulos
    The American Journal of Pathology 2010 176 6
  • Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα
    Mariana Nacht, Lixin Qiao, Michael P. Sheets, Thia St. Martin, Matthew Labenski, Hormoz Mazdiyasni, Russell Karp, Zhendong Zhu, Prasoon Chaturvedi, Deepa Bhavsar, Deqiang Niu, William Westlin, Russell C. Petter, Aravind Prasad Medikonda, Juswinder Singh
    Journal of Medicinal Chemistry 2013 56 3
  • ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
    Takeshi Yoshida, Lanxi Song, Yun Bai, Fumi Kinose, Jiannong Li, Kim C. Ohaegbulam, Teresita Muñoz-Antonia, Xiaotao Qu, Steven Eschrich, Hidetaka Uramoto, Fumihiro Tanaka, Patrick Nasarre, Robert M. Gemmill, Joëlle Roche, Harry A. Drabkin, Eric B. Haura, Pier Giorgio Petronini
    PLOS ONE 2016 11 1
  • EGFR kinase domain mutations – functional impact and relevance for lung cancer therapy
    D Irmer, J O Funk, A Blaukat
    Oncogene 2007 26 39
  • ErbBs in lung cancer
    Sreenath V. Sharma, Jeffrey Settleman
    Experimental Cell Research 2009 315 4
  • Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer
    Takeshi Yoshida, Guolin Zhang, Eric B. Haura
    Biochemical Pharmacology 2010 80 5
  • p85α SH2 Domain Phosphorylation by IKK Promotes Feedback Inhibition of PI3K and Akt in Response to Cellular Starvation
    William C. Comb, Jessica E. Hutti, Patricia Cogswell, Lewis C. Cantley, Albert S. Baldwin
    Molecular Cell 2012 45 6
  • A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer
    David M. Jackman, Leigh A. Cioffredi, Lorraine Jacobs, Farhana Sharmeen, Linda K. Morse, Joan Lucca, Scott R. Plotkin, Paul J. Marcoux, Michael S. Rabin, Thomas J. Lynch, Bruce E. Johnson, Santosh Kesari
    Oncotarget 2015 6 6
  • Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells
    Joshua Bliesath, Nanni Huser, Mayuko Omori, Daniel Bunag, Chris Proffitt, Nicole Streiner, Caroline Ho, Adam Siddiqui-Jain, Sean E. O’Brien, John K.C. Lim, David M. Ryckman, Kenna Anderes, William G. Rice, Denis Drygin
    Cancer Letters 2012 322 1
  • Pharmacogenomics steps toward personalized medicine
    Hong-Guang Xie, Felix W Frueh
    Personalized Medicine 2005 2 4
  • Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib
    K Yonesaka, K Hirotani, H Kawakami, M Takeda, H Kaneda, K Sakai, I Okamoto, K Nishio, P A Jänne, K Nakagawa
    Oncogene 2016 35 7
  • Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells
    Brent N Rexer, Siprachanh Chanthaphaychith, Kimberly Brown Dahlman, Carlos L Arteaga
    Breast Cancer Research 2014 16 1
  • Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
    Brent N. Rexer, Ritwik Ghosh, Archana Narasanna, Mónica Valeria Estrada, Anindita Chakrabarty, Youngchul Song, Jeffrey A. Engelman, Carlos L. Arteaga
    Clinical Cancer Research 2013 19 19
  • Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells
    Shu-Yan Han, Ming-Bo Zhao, Gui-Bao Zhuang, Ping-Ping Li
    Lung Cancer 2012 75 1
  • Delphinidin Reduces Cell Proliferation and Induces Apoptosis of Non-Small-Cell Lung Cancer Cells by Targeting EGFR/VEGFR2 Signaling Pathways
    Harish Chandra Pal, Samriti Sharma, Leah Ray Strickland, Jyoti Agarwal, Mohammad Athar, Craig A. Elmets, Farrukh Afaq, Xianglin Shi
    PLoS ONE 2013 8 10
  • Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines
    Maria S. Pino, Michele Balsamo, Francesca Di Modugno, Marcella Mottolese, Massimo Alessio, Elisa Melucci, Michele Milella, David J. McConkey, Ulrike Philippar, Frank B. Gertler, Pier Giorgio Natali, Paola Nisticò
    Clinical Cancer Research 2008 14 15
  • Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer
    Johannes M. Heuckmann, Daniel Rauh, Roman K. Thomas
    Journal of Clinical Oncology 2012 30 27
  • Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH+ lung cancer stem cells through IGF1R signaling
    I G Kim, S Y Kim, S I Choi, J H Lee, K C Kim, E W Cho
    Oncogene 2014 33 30
  • Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring HER 2 oncogene alterations
    Ken Suzawa, Shinichi Toyooka, Masakiyo Sakaguchi, Mizuki Morita, Hiromasa Yamamoto, Shuta Tomida, Tomoaki Ohtsuka, Mototsugu Watanabe, Shinsuke Hashida, Yuho Maki, Junichi Soh, Hiroaki Asano, Kazunori Tsukuda, Shinichiro Miyoshi
    Cancer Science 2016 107 1
  • HER3, serious partner in crime
    Arjan Kol, Anton G.T. Terwisscha van Scheltinga, Hetty Timmer-Bosscha, Laetitia E. Lamberts, Frederike Bensch, Elisabeth G.E. de Vries, Carolina P. Schröder
    Pharmacology & Therapeutics 2014 143 1
  • Microenvironment-Derived HGF Overcomes Genetically Determined Sensitivity to Anti-MET Drugs
    Selma Pennacchietti, Manuela Cazzanti, Andrea Bertotti, William M. Rideout, May Han, Jeno Gyuris, Timothy Perera, Paolo M. Comoglio, Livio Trusolino, Paolo Michieli
    Cancer Research 2014 74 22
  • Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridization—Why, When, and How?
    Rafal Dziadziuszko, Fred R. Hirsch, Marileila Varella-Garcia, Paul A. Bunn
    Clinical Cancer Research 2006 12 14
  • Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas
    Juliana Eng, Kaitlin M. Woo, Camelia S. Sima, Andrew Plodkowski, Matthew D. Hellmann, Jamie E. Chaft, Mark G. Kris, Maria E. Arcila, Marc Ladanyi, Alexander Drilon
    Journal of Thoracic Oncology 2015 10 12
  • A kinase-independent function of AKT promotes cancer cell survival
    Igor Vivanco, Zhi C Chen, Barbara Tanos, Barbara Oldrini, Wan-Ying Hsieh, Nicolas Yannuzzi, Carl Campos, Ingo K Mellinghoff
    eLife 2014 3
  • Current Challenges in Personalized Cancer Medicine
    Anthony C. Faber, Hiromichi Ebi, Carlotta Costa, Jeffrey A. Engelman
    2012 65
  • ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma
    J. Spencer Liles, J. Pablo Arnoletti, Ching-Wei D. Tzeng, J. Harrison Howard, Andrew V. Kossenkov, Peter Kulesza, Martin J. Heslin, Andrey Frolov
    Cancer Biology & Therapy 2010 10 6
  • Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation
    Tiziana Servidei, Anna Riccardi, Maurizio Sanguinetti, Carlo Dominici, Riccardo Riccardi
    Journal of Cellular Physiology 2006 208 1
  • Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models
    Shining Wang, Ping Guo, Xiaomin Wang, Qingyu Zhou, James M. Gallo
    Molecular Cancer Therapeutics 2008 7 2
  • Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression
    Toru Mukohara, Hiroyuki Shimada, Naomi Ogasawara, Ryoko Wanikawa, Manami Shimomura, Tetsuya Nakatsura, Genichiro Ishii, Joon Oh Park, Pasi A. Jänne, Nagahiro Saijo, Hironobu Minami
    Cancer Letters 2009 282 1
  • Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation
    Akiko Uchida, Seiki Hirano, Hiroyuki Kitao, Atsuko Ogino, Kanmei Rai, Shinichi Toyooka, Nagio Takigawa, Masahiro Tabata, Minoru Takata, Katsuyuki Kiura, Mitsune Tanimoto
    Cancer Science 2007 98 3
  • Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature
    Dongqing Gu, William A. Scaringe, Kai Li, Juan-Sebastian Saldivar, Kathleen A. Hill, Zhenbin Chen, Kelly D. Gonzalez, Steve S. Sommer
    Human Mutation 2007 28 8
  • Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
    Mari Iida, Toni M Brand, Megan M Starr, Evan J Huppert, Neha Luthar, Harsh Bahrar, John P Coan, Hannah E Pearson, Ravi Salgia, Deric L Wheeler
    Molecular Cancer 2014 13 1
  • Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update
    Ayodele Ayoola, Amit Barochia, Kiran Belani, Chandra P. Belani
    Cancer Investigation 2012 30 5
  • Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors
    Yun Jung Choi, Jin Kyung Rho, Byung-suk Jeon, Su Jin Choi, Su Cheol Park, Seung Sook Lee, Hye-Ryoun Kim, Cheol Hyeon Kim, Jae Cheol Lee
    Cancer Chemotherapy and Pharmacology 2010 66 2
  • Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18
    Silvia Carvalho, Francesca Levi-Schaffer, Michael Sela, Yosef Yarden
    British Journal of Pharmacology 2016 173 9
  • Pathogenic Activation of Receptor Tyrosine Kinases in Mammalian Membranes
    Lijuan He, Kalina Hristova
    Journal of Molecular Biology 2008 384 5
  • Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
    Jiannong Li, Keiryn Bennett, Alexey Stukalov, Bin Fang, Guolin Zhang, Takeshi Yoshida, Isamu Okamoto, Jae‐Young Kim, Lanxi Song, Yun Bai, Xiaoning Qian, Bhupendra Rawal, Michael Schell, Florian Grebien, Georg Winter, Uwe Rix, Steven Eschrich, Jacques Colinge, John Koomen, Giulio Superti‐Furga, Eric B Haura
    Molecular Systems Biology 2013 9 1
  • Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis
    T Smirnova, Z N Zhou, R J Flinn, J Wyckoff, P J Boimel, M Pozzuto, S J Coniglio, J M Backer, A R Bresnick, J S Condeelis, N E Hynes, J E Segall
    Oncogene 2012 31 6
  • Cisplatin influences acquisition of resistance to molecular‐targeted agents through epithelial–mesenchymal transition‐like changes
    Maki Kurokawa, Nobuyuki Ise, Kazuya Omi, Katsutoshi Goishi, Shigeki Higashiyama
    Cancer Science 2013 104 7
  • Amphiregulin Promotes BAX Inhibition and Resistance to Gefitinib in Non-small-cell Lung Cancers
    Benoît Busser, Lucie Sancey, Véronique Josserand, Carole Niang, Marie C Favrot, Jean-Luc Coll, Amandine Hurbin
    Molecular Therapy 2010 18 3
  • Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer
    S M Pontier, L Huck, D E White, J Rayment, V Sanguin-Gendreau, B Hennessy, D Zuo, R St-Arnaud, G B Mills, S Dedhar, C J Marshall, W J Muller
    Oncogene 2010 29 23
  • MicroRNA-219-2-3p Functions as a Tumor Suppressor in Gastric Cancer and Is Regulated by DNA Methylation
    Huizi Lei, Dongling Zou, Zheng Li, Min Luo, Lei Dong, Bin Wang, Haixin Yin, Yanni Ma, Changzheng Liu, Fang Wang, Junwu Zhang, Jia Yu, Yu Li, Arun Rishi
    PLoS ONE 2013 8 4
  • Modeling oncogene addiction using RNA interference
    S. M. Rothenberg, J. A. Engelman, S. Le, D. J. Riese, D. A. Haber, J. Settleman
    Proceedings of the National Academy of Sciences 2008 105 34
  • Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer: Fig. 1.
    Bruce E. Johnson, David Jackman, Pasi A. Jänne
    Clinical Cancer Research 2007 13 15
  • The Asn418-Linked N-Glycan of ErbB3 Plays a Crucial Role in Preventing Spontaneous Heterodimerization and Tumor Promotion
    Shunichi Yokoe, Motoko Takahashi, Michio Asahi, Seung Ho Lee, Wei Li, Daisuke Osumi, Eiji Miyoshi, Naoyuki Taniguchi
    Cancer Research 2007 67 5
  • Detection of Oncogenic Mutations in the EGFR Gene in Lung Adenocarcinoma with Differential Sensitivity to EGFR Tyrosine Kinase Inhibitors
    R.K. THOMAS, H. GREULICH, Y. YUZA, J.C. LEE, T. TENGS, W. FENG, T.-H. CHEN, E. NICKERSON, J. SIMONS, M. EGHOLM, J.M. ROTHBERG, W.R. SELLERS, M.L. MEYERSON
    Cold Spring Harbor Symposia on Quantitative Biology 2005 70
  • ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models
    Li Zhang, Carla Castanaro, Bo Luan, Katie Yang, Liangfen Fan, Jeanette L. Fairhurst, Ashique Rafique, Terra B. Potocky, Jing Shan, Frank J. Delfino, Ergang Shi, Tammy Huang, Joel H. Martin, Gang Chen, Douglas MacDonald, John S. Rudge, Gavin Thurston, Christopher Daly
    Molecular Cancer Therapeutics 2014 13 5
  • InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
    Yufang Ma, Nan Tang, Reid C. Thompson, Bret C. Mobley, Steven W. Clark, Jann N. Sarkaria, Jialiang Wang
    Clinical Cancer Research 2016 22 7
  • HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells
    Dhara N. Amin, Natalia Sergina, Lionel Lim, Andrei Goga, Mark M. Moasser
    Biochemical Journal 2012 447 3
  • Impaired SHP2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Growth Factor Receptor–Activating Mutations
    Matthew J. Lazzara, Keara Lane, Richard Chan, Paul J. Jasper, Michael B. Yaffe, Peter K. Sorger, Tyler Jacks, Benjamin G. Neel, Douglas A. Lauffenburger
    Cancer Research 2010 70 9
  • Intratumoral Epiregulin Is a Marker of Advanced Disease in Non–Small Cell Lung Cancer Patients and Confers Invasive Properties on EGFR-Mutant Cells
    Jie Zhang, Kentaro Iwanaga, Kuicheon C. Choi, Marie Wislez, Maria Gabriela Raso, Wei Wei, Ignacio I. Wistuba, Jonathan M. Kurie
    Cancer Prevention Research 2008 1 3
  • Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors
    Md Jawaid Akhtar, Anees Ahmad Siddiqui, Ahsan Ahmed Khan, Zulphikar Ali, Rikeshwer Prasad Dewangan, Santosh Pasha, M. Shahar Yar
    European Journal of Medicinal Chemistry 2017 126
  • Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
    Dana S. Neel, Trever G. Bivona
    npj Precision Oncology 2017 1 1
  • EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib
    Jian Ming Xu, Yu Han, Hai Qing Duan, E. Mei Gao, Yang Zhang, Xiao Qing Liu, Jing Sheng Zhang, Luca Toschi, Domenico Galetta, Amalia Azzariti, Angelo Paradiso
    Journal of Cancer Research and Clinical Oncology 2009 135 6
  • Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: A review of published data
    Giannis Mountzios, Meletios-Athanassios Dimopoulos, Jean-Charles Soria, Despina Sanoudou, Christos A. Papadimitriou
    Critical Reviews in Oncology/Hematology 2010 75 2
  • Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer
    Lynnette Fernandez-Cuesta, Roman K. Thomas
    Clinical Cancer Research 2015 21 9
  • Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models
    Yi-He Ling, Miguel Aracil, José Jimeno, Roman Perez-Soler, Yiyu Zou
    European Journal of Cancer 2009 45 10
  • Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib
    Tiziana Servidei, Anna Riccardi, Simona Mozzetti, Cristiano Ferlini, Riccardo Riccardi
    International Journal of Cancer 2008 123 12
  • ERBB oncogene proteins as targets for monoclonal antibodies
    O. L. Polanovski, E. N. Lebedenko, S. M. Deyev
    Biochemistry (Moscow) 2012 77 3
  • ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC)
    S.E. Witta, R. Dziadziuszko, K. Yoshida, K. Hedman, M. Varella-Garcia, P.A. Bunn, F.R. Hirsch
    Annals of Oncology 2009 20 4
  • A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells
    HYUNSEUNG LEE, SOO JUNG KIM, KYUNG HEE JUNG, MI KWON SON, HONG HUA YAN, SUNGWOO HONG, SOON-SUN HONG
    Oncology Reports 2013 30 2
  • Targeting ADAMS and ERBBs in lung cancer
    Nancy E. Hynes, Thomas Schlange
    Cancer Cell 2006 10 1
  • The Role of Targeting Mammalian Target of Rapamycin in Lung Cancer
    Sumanta Kumar Pal, Robert A. Figlin, Karen L. Reckamp
    Clinical Lung Cancer 2008 9 6
  • Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going
    Rafael Rosell, Mauricio Cuello, Fabiana Cecere, Mariacarmela Santarpia, Noemi Reguart, Enriqueta Felip, Miquel Taron
    Current Opinion in Oncology 2006 18 2
  • Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck
    Susanne J Rogers, Carol Box, Philip Chambers, Yolanda Barbachano, Christopher M Nutting, Peter Rhŷs-Evans, Paul Workman, Kevin J Harrington, Suzanne A Eccles
    The Journal of Pathology 2009 218 1
  • Targeting EGFR in Non–Small-Cell Lung Cancer
    James H. Doroshow
    New England Journal of Medicine 2005 353 2
  • Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients
    Niels Reinmuth, Anna Jauch, Elizabeth Chang Xu, Thomas Muley, Martin Granzow, Hans Hoffmann, Hendrik Dienemann, Esther Herpel, Philipp A. Schnabel, Felix J.F. Herth, Sandra Gottschling, Harald Lahm, Martin Steins, Michael Thomas, Michael Meister
    Lung Cancer 2008 62 2
  • EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells
    Lene Melsæther Grøvdal, Jiyoung Kim, Mikkel Roland Holst, Stine Louise Jeppe Knudsen, Michael Vibo Grandal, Bo van Deurs
    Cellular Signalling 2012 24 1
  • Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells
    Parnetta Sutton, Jeffrey A Borgia, Philip Bonomi, Janet MD Plate
    Molecular Cancer 2013 12 1
  • Multifunctional receptor-targeting antibodies for cancer therapy
    Yanni Zhu, Sung Hugh Choi, Khalid Shah
    The Lancet Oncology 2015 16 15
  • Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer: Fig. 1.
    Bruce E. Johnson, Pasi A. Jänne
    Clinical Cancer Research 2006 12 14
  • Altered serine/threonine kinase activity in schizophrenia
    Jennifer L. McGuire, John H. Hammond, Stefani D. Yates, Dongquan Chen, Vahram Haroutunian, James H. Meador-Woodruff, Robert E. McCullumsmith
    Brain Research 2014 1568
  • Decreased internalisation of ErbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib
    B.S. Hendriks, G.J. Griffiths, R. Benson, D. Kenyon, M. Lazzara, J. Swinton, S. Beck, M. Hickinson, J.M. Beusmans, D. Lauffenburger, D. de Graaf
    IEE Proceedings - Systems Biology 2006 153 6
  • Paired Overexpression of ErbB3 and Sox10 in Pilocytic Astrocytoma
    Steven O. Addo-Yobo, Jennifer Straessle, Adil Anwar, Andrew M. Donson, B. K. Kleinschmidt-DeMasters, Nicholas K. Foreman
    Journal of Neuropathology & Experimental Neurology 2006 65 8
  • Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer
    Asuka Nakata, Noriko Gotoh
    Expert Opinion on Therapeutic Targets 2012 16 8
  • The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck
    Susanne J Rogers, Carol Box, Kevin J Harrington, Chris Nutting, Peter Rhys-Evans, Suzanne A Eccles
    Expert Opinion on Therapeutic Targets 2005 9 4
  • Two-in-One antibodies with dual action Fabs
    Charles Eigenbrot, Germaine Fuh
    Current Opinion in Chemical Biology 2013 17 3
  • Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
    Marta Guix, Anthony C. Faber, Shizhen Emily Wang, Maria Graciela Olivares, Youngchul Song, Sherman Qu, Cammie Rinehart, Brenda Seidel, Douglas Yee, Carlos L. Arteaga, Jeffrey A. Engelman
    Journal of Clinical Investigation 2008
  • Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations
    C M Furcht, A R Muñoz Rojas, D Nihalani, M J Lazzara
    Oncogene 2013 32 18
  • Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology
    Amit J. Sabnis, Trever G. Bivona
    Trends in Molecular Medicine 2019 25 3
  • Targeting EGFR in lung cancer: Lessons learned and future perspectives
    Conor E. Steuer, Suresh S. Ramalingam
    Molecular Aspects of Medicine 2015 45
  • FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling
    C Daly, C Castanaro, W Zhang, Q Zhang, Y Wei, M Ni, T M Young, L Zhang, E Burova, G Thurston
    Oncogene 2017 36 4
  • Y-box Binding Protein-1 Contributes to Both HER2/ErbB2 Expression and Lapatinib Sensitivity in Human Gastric Cancer Cells
    Tomohiro Shibata, Hitoshi Kan, Yuichi Murakami, Hiroki Ureshino, Kosuke Watari, Akihiko Kawahara, Masayoshi Kage, Satoshi Hattori, Mayumi Ono, Michihiko Kuwano
    Molecular Cancer Therapeutics 2013 12 5
  • A Curious Link Between Epidermal Growth Factor Receptor Amplification and Survival: Effect of “Allele Dilution” on Gefitinib Sensitivity?
    Frederic J. Kaye
    JNCI: Journal of the National Cancer Institute 2005 97 9
  • Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors
    Bernard Barlaam, Judith Anderton, Peter Ballard, Robert H. Bradbury, Laurent F. A. Hennequin, D. Mark Hickinson, Jason G. Kettle, George Kirk, Teresa Klinowska, Christine Lambert-van der Brempt, Cath Trigwell, John Vincent, Donald Ogilvie
    ACS Medicinal Chemistry Letters 2013 4 8
  • Engineered Bivalent Ligands to Bias ErbB Receptor-mediated Signaling and Phenotypes*
    Steven M. Jay, Elma Kurtagic, Luis M. Alvarez, Seymour de Picciotto, Edgar Sanchez, Jessica F. Hawkins, Robin N. Prince, Yadir Guerrero, Carolyn L. Treasure, Richard T. Lee, Linda G. Griffith
    Journal of Biological Chemistry 2011 286 31
  • LYN-activating mutations mediate antiestrogen resistance in estrogen receptor–positive breast cancer
    Luis J. Schwarz, Emily M. Fox, Justin M. Balko, Joan T. Garrett, María Gabriela Kuba, Mónica Valeria Estrada, Ana María González-Angulo, Gordon B. Mills, Monica Red-Brewer, Ingrid A. Mayer, Vandana Abramson, Monica Rizzo, Mark C. Kelley, Ingrid M. Meszoely, Carlos L. Arteaga
    Journal of Clinical Investigation 2014 124 12
  • The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance ofepidermal growth factor receptormutant lung cancer cells triggered by hepatocyte growth factor
    Takako Sano, Shinji Takeuchi, Takayuki Nakagawa, Daisuke Ishikawa, Shigeki Nanjo, Tadaaki Yamada, Takahiro Nakamura, Kunio Matsumoto, Seiji Yano
    International Journal of Cancer 2013 133 2
  • The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling
    Ryan Williams, Amanda F. Baker, Nathan T. Ihle, Ashley R. Winkler, Lynn Kirkpatrick, Garth Powis
    Cancer Chemotherapy and Pharmacology 2006 58 4
  • Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors
    Myung Hee Chang, Hee Kyung Ahn, Jeeyun Lee, Chan-Kwon Jung, Yoon-La Choi, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
    Cancer 2011 117 1
  • Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase
    Kenji Takeuchi, Tomohiro Shin-ya, Kazuto Nishio, Fumiaki Ito
    FEBS Journal 2009 276 5
  • Oncogenes Come of Age
    H. VARMUS, W. PAO, K. POLITI, K. PODSYPANINA, Y.-C.N. DU
    Cold Spring Harbor Symposia on Quantitative Biology 2005 70
  • RETRACTED: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase
    Peter Littlefield, Mark M. Moasser, Natalia Jura
    Chemistry & Biology 2014 21 4
  • HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma
    Hee Jin Lee, Joon-Yong Chung, Stephen M. Hewitt, Eunsil Yu, Seung-Mo Hong
    Virchows Archiv 2012 461 5
  • The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response—Biological and Clinical Aspects
    Michaela Medová, Daniel Aebersold, Yitzhak Zimmer
    Cancers 2013 6 1
  • Arginine 383 is a crucial residue in ABCG2 biogenesis
    Orsolya Polgar, Lilangi S. Ediriwickrema, Robert W. Robey, Ajay Sharma, Ramanujan S. Hegde, Yongfu Li, Di Xia, Yvona Ward, Michael Dean, Csilla Ozvegy-Laczka, Balazs Sarkadi, Susan E. Bates
    Biochimica et Biophysica Acta (BBA) - Biomembranes 2009 1788 7
  • Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR
    Shu-Yan Han, Hui-Rong Ding, Wei Zhao, Fei Teng, Ping-Ping Li
    BMC Complementary and Alternative Medicine 2014 14 1
  • Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3
    Malgorzata Magdalena Sak, Monika Szymanska, Vibeke Bertelsen, Max Hasmann, Inger Helene Madshus, Espen Stang
    Carcinogenesis 2013 34 9
  • An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival
    Keman Zhang, Poki Wong, Jiaqi Duan, Barbara Jacobs, Ernest C. Borden, Barbara Bedogni
    Pigment Cell & Melanoma Research 2013 26 3
  • Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway
    Sauveur-Michel Maira, Pascal Furet, Frédéric Stauffer
    Future Medicinal Chemistry 2009 1 1
  • HER3 as a Therapeutic Target in Cancer
    Niki Karachaliou, Chiara Lazzari, Alberto Verlicchi, Aaron E. Sosa, Rafael Rosell
    BioDrugs 2017 31 1
  • Ligands of Epidermal Growth Factor Receptor and the Insulin-Like Growth Factor Family as Serum Biomarkers for Response to Epidermal Growth Factor Receptor Inhibitors in Patients with Advanced Non-small Cell Lung Cancer
    Marieke A. Vollebergh, Ingrid Kappers, Houke M. Klomp, Johanna C. Buning-Kager, Catharina M. Korse, Michael Hauptmann, Karin E. de Visser, Michel M. van den Heuvel, Sabine C. Linn
    Journal of Thoracic Oncology 2010 5 12
  • Molecular Predictors of Prognosis in Lung Cancer
    Jules Lin, David G. Beer
    Annals of Surgical Oncology 2012 19 2
  • P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment
    Yi-Fan Zhao, Chong-Ren Wang, Yan-Ming Wu, Sheng-Lin Ma, Yuan Ji, Yan-Jun Lu
    Biomedicine & Pharmacotherapy 2011 65 3
  • Perspectives for targeted therapies in cancer of unknown primary site
    George Pentheroudakis, Nicholas Pavlidis
    Cancer Treatment Reviews 2006 32 8
  • An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC
    Kimio Yonesaka, Naoki Takegawa, Satomi Watanabe, Koji Haratani, Hisato Kawakami, Kazuko Sakai, Yasutaka Chiba, Naoyuki Maeda, Takashi Kagari, Kenji Hirotani, Kazuto Nishio, Kazuhiko Nakagawa
    Oncogene 2019 38 9
  • Diacylglycerol Kinase δ Modulates Akt Phosphorylation through Pleckstrin Homology Domain Leucine-rich Repeat Protein Phosphatase 2 (PHLPP2)
    Tracy M. Crotty, Tomoyuki Nakano, Diana M. Stafforini, Matthew K. Topham
    Journal of Biological Chemistry 2013 288 3
  • ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells
    Hyunji Lee, Hyunjung Lee, Hyunjung Chin, Kyoungmi Kim, Daekee Lee
    Oncotarget 2014 5 13
  • Gefitinib Induction of In vivo Detectable Signals by Bcl-2/Bcl-xL Modulation of Inositol Trisphosphate Receptor Type 3
    Antonella Zannetti, Francesca Iommelli, Rosa Fonti, Angela Papaccioli, Jvana Sommella, Anna Lettieri, Giuseppe Pirozzi, Roberto Bianco, Giampaolo Tortora, Marco Salvatore, Silvana Del Vecchio
    Clinical Cancer Research 2008 14 16
  • Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants
    Byung Min Chung
    World Journal of Clinical Oncology 2014 5 5
  • Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients
    Elena Yaiza Romero-Ventosa, Sonia Blanco-Prieto, Ana Lourdes González-Piñeiro, Francisco Javier Rodríguez-Berrocal, Guadalupe Piñeiro-Corrales, María Páez de la Cadena
    SpringerPlus 2015 4 1
  • Prevalence, Clinicopathologic Characteristics, and Molecular Associations of EGFR Exon 20 Insertion Mutations in East Asian Patients with Lung Adenocarcinoma
    Yunjian Pan, Yang Zhang, Yuan Li, Haichuan Hu, Lei Wang, Hang Li, Rui Wang, Ting Ye, Xiaoyang Luo, Yiliang Zhang, Bin Li, Deng Cai, Lei Shen, Yihua Sun, Haiquan Chen
    Annals of Surgical Oncology 2014 21 S4
  • Induction of lung adenocarcinoma in transgenic mice expressing activatedEGFRdriven by the SP-C promoter
    Kadoaki Ohashi, Kammei Rai, Yoshiro Fujiwara, Masahiro Osawa, Seiki Hirano, Katsuyoshi Takata, Eisaku Kondo, Tadashi Yoshino, Minoru Takata, Mitsune Tanimoto, Katsuyuki Kiura
    Cancer Science 2008 99 9
  • Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer
    Niels Reinmuth, Michael Meister, Thomas Muley, Martin Steins, Michael Kreuter, Felix J.F. Herth, Hans Hoffmann, Hendrik Dienemann, Michael Thomas
    International Journal of Cancer 2006 119 4
  • PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy
    M J Fidler, L E Morrison, S Basu, L Buckingham, K Walters, M Batus, K K Jacobson, S S Jewell, J Coon, P D Bonomi
    British Journal of Cancer 2011 105 12
  • Reciprocal Negative Regulation between EGFR and DEPTOR Plays an Important Role in the Progression of Lung Adenocarcinoma
    Xuefeng Zhou, Jialong Guo, Yanmei Ji, Gaofeng Pan, Tao Liu, Hua Zhu, Jinping Zhao
    Molecular Cancer Research 2016 14 5
  • Sprouty 2 Regulates DNA Damage-induced Apoptosis in Ras-transformed Human Fibroblasts
    Piro Lito, Bryan D. Mets, Daniel M. Appledorn, Veronica M. Maher, J. Justin McCormick
    Journal of Biological Chemistry 2009 284 2
  • Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation
    Toshimitsu Yamaoka, Tohru Ohmori, Motoi Ohba, Satoru Arata, Yasunari Kishino, Yasunori Murata, Sojiro Kusumoto, Hiroo Ishida, Takao Shirai, Takashi Hirose, Tsukasa Ohnishi, Yasutsuna Sasaki
    Molecular Cancer Therapeutics 2016 15 12
  • Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice
    Kadoaki Ohashi, Nagio Takigawa, Masahiro Osawa, Eiki Ichihara, Hiromasa Takeda, Toshio Kubo, Seiki Hirano, Tadashi Yoshino, Minoru Takata, Mitsune Tanimoto, Katsuyuki Kiura
    Cancer Research 2009 69 17
  • Combined treatment with TNF-α/gefitinib alleviates the resistance to gefitinib in PC-9 cells
    Yuan Ji, Sheng-lin Ma, Yi-ping Zhang, Juan-juan Tang, Yan-ming Wu, Yan-Jun Lu
    Anti-Cancer Drugs 2009 20 9
  • ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas
    Xiaoling Song, Pang-Dian Fan, Amlak Bantikassegn, Udayan Guha, David W. Threadgill, Harold Varmus, Katerina Politi
    Cancer Research 2015 75 6
  • HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285
    Shinji Takagi, Hiroshi Banno, Akira Hayashi, Toshiya Tamura, Tomoyasu Ishikawa, Yoshikazu Ohta
    Oncoscience 2014 1 3
  • ErbB3 Inhibitory Surrobodies Inhibit Tumor Cell Proliferation In Vitro and In Vivo
    Pamela K. Foreman, Medini Gore, Philip A. Kobel, Li Xu, Helena Yee, Charles Hannum, Hoangdung Ho, Sandra M. Wang, Hieu V. Tran, Michael Horowitz, Lawrence Horowitz, Ramesh R. Bhatt
    Molecular Cancer Therapeutics 2012 11 7
  • Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells
    Tsuyoshi Ohta, Masahide Ohmichi, Tae Shibuya, Toshifumi Takahashi, Seiji Tsutsumi, Kazuhiro Takahashi, Hirohisa Kurachi
    Cancer Biology & Therapy 2012 13 6
  • Gefitinib-Sensitive EGFR Lacking Residues 746–750 Exhibits Hypophosphorylation at Tyrosine Residue 1045, Hypoubiquitination, And Impaired Endocytosis
    Mitsugi Furukawa, Izumi Nagatomo, Toru Kumagai, Tadahiro Yamadori, Ryo Takahashi, Mana Yoshimura, Tsutomu Yoneda, Yoshito Takeda, Sho Goya, Hiroto Matsuoka, Takashi Kijima, Mitsuhiro Yoshida, Tadashi Osaki, Isao Tachibana, Mark I. Greene, Ichiro Kawase
    DNA and Cell Biology 2007 26 3
  • Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma
    Chandraiah Godugu, Ravi Doddapaneni, Apurva R Patel, Rakesh Singh, Roger Mercer, Mandip Singh
    Pharmaceutical Research 2016 33 1
  • SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2
    Afshin Dowlati, Amy Kluge, David Nethery, Balazs Halmos, Jeffrey A. Kern
    Anti-Cancer Drugs 2008 19 1
  • α-Catenin homodimers are recruited to phosphoinositide-activated membranes to promote adhesion
    Megan N. Wood, Noboru Ishiyama, Indira Singaram, Connie M. Chung, Annette S. Flozak, Alex Yemelyanov, Mitsu Ikura, Wonhwa Cho, Cara J. Gottardi
    Journal of Cell Biology 2017 216 11
  • Correlation between EGFR gene mutation pattern and Akt phosphorylation in pulmonary adenocarcinomas
    Satoshi Ikeda, Kazuhiko Takabe, Masaharu Inagaki, Naoya Funakoshi, Keiko Suzuki, Toshikatsu Shibata
    Pathology International 2007 57 5
  • Down-regulation of epidermal growth factor receptor by curcumin-induced UBE1L in human bronchial epithelial cells
    A-Pei Jiang, Dong-Hu Zhou, Xu-Lian Meng, Ai-Ping Zhang, Cui Zhang, Xiao-Ting Li, Qing Feng
    The Journal of Nutritional Biochemistry 2014 25 2
  • Increased expression of the integral membrane protein ErbB2 in Chinese hamster ovary cells expressing the anti-apoptotic gene Bcl-xL
    Shannon O’Connor, Edwin Li, Brian S. Majors, Lijuan He, Jesse Placone, Deniz Baycin, Michael J. Betenbaugh, Kalina Hristova
    Protein Expression and Purification 2009 67 1
  • Targeting HER (ERBB) signaling in head and neck cancer: An essential update
    Jun Zhang, Nabil F. Saba, Georgia (Zhuo) Chen, Dong M. Shin
    Molecular Aspects of Medicine 2015 45
  • Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer
    Xuemei Yang, Alexa B. Turke, Jie Qi, Youngchul Song, Brent N. Rexer, Todd W. Miller, Pasi A. Jänne, Carlos L. Arteaga, Lewis C. Cantley, Jeffrey A. Engelman, John M. Asara
    Cancer Research 2011 71 18
  • Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells
    JIXIA LI, BIHUA LIN, XIANGYONG LI, XUDONG TANG, ZHIWEI HE, KEYUAN ZHOU
    Oncology Reports 2015 33 2
  • Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer
    Finn Edler von Eyben
    Critical Reviews in Clinical Laboratory Sciences 2006 43 4
  • Flotillin depletion affects ErbB protein levels in different human breast cancer cells
    Nagham Asp, Sascha Pust, Kirsten Sandvig
    Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2014 1843 9
  • Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
    Christopher Delaney, Samuel Frank, R Stephanie Huang
    Chinese Journal of Cancer 2015 34 3
  • Targeting the PI3K/Akt/mTOR Pathway in Malignancy: Rationale and Clinical Outlook
    Daniel C. Cho
    BioDrugs 2014 28 4
  • The Gefitinib-Sensitizing Mutant Epidermal Growth Factor Receptor Enables Transformation of a Mouse Fibroblast Cell Line
    Izumi Nagatomo, Toru Kumagai, Tadahiro Yamadori, Mitsugi Furukawa, Ryo Takahashi, Tsutomu Yoneda, Yoshitaka Ogata, Yoshiyuki Saito, Koji Inoue, Yukihiro Yano, Takashi Kijima, Mitsuhiro Yoshida, Tadashi Osaki, Isao Tachibana, Mark I. Greene, Ichiro Kawase
    DNA and Cell Biology 2006 25 4
  • EGFR Inhibition Fails to Suppress Vascular Proliferation and Tumor Growth in a Ewing's Sarcoma Model
    Artur Chernoguz, Kelly Crawford, Eileen Donovan, Abbey Vandersall, Caroline Berglund, Timothy P. Cripe, Jason S. Frischer
    Journal of Surgical Research 2012 173 1
  • Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR
    YOUNG-SOO HONG, WON-JUN JANG, KYUNG-SOO CHUN, CHUL-HO JEONG
    Oncology Reports 2014 31 6
  • The Role of PI3K in Met Driven Cancer: A Recap
    Alexia Hervieu, Stéphanie Kermorgant
    Frontiers in Molecular Biosciences 2018 5
  • Anti-tumor efficacy of naked siRNAs for ERBB3 or AKT2 against lung adenocarcinoma cell xenografts
    Gunamani Sithanandam, Laura W. Fornwald, Janet R. Fields, Nicole L. Morris, Lucy M. Anderson
    International Journal of Cancer 2012 130 2
  • Antitumor Impact of p14ARF on Gefitinib-Resistant Non–Small Cell Lung Cancers
    Ken Saito, Nagio Takigawa, Naoko Ohtani, Hidekazu Iioka, Yuki Tomita, Ryuzo Ueda, Junya Fukuoka, Kazuhiko Kuwahara, Eiki Ichihara, Katsuyuki Kiura, Eisaku Kondo
    Molecular Cancer Therapeutics 2013 12 8
  • CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
    Jeffrey H. Becker, Yandi Gao, Margaret Soucheray, Ines Pulido, Eiki Kikuchi, María L. Rodríguez, Rutu Gandhi, Aranzazu Lafuente-Sanchis, Miguel Aupí, Javier Alcácer Fernández-Coronado, Paloma Martín-Martorell, Antonio Cremades, José M. Galbis-Caravajal, Javier Alcácer, Camilla L. Christensen, Patricia Simms, Ashley Hess, Hajime Asahina, Michael P. Kahle, Fatima Al-Shahrour, Jeffrey A. Borgia, Agustín Lahoz, Amelia Insa, Oscar Juan, Pasi A. Jänne, Kwok-Kin Wong, Julian Carretero, Takeshi Shimamura
    Cancer Research 2019 79 17
  • ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation
    Michelle M. Williams, David B. Vaught, Meghan Morrison Joly, Donna J. Hicks, Violeta Sanchez, Philip Owens, Bushra Rahman, David L. Elion, Justin M. Balko, Rebecca S. Cook
    Breast Cancer Research 2017 19 1
  • Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase Inhibitors
    Sei-Hoon Yang
    Tuberculosis and Respiratory Diseases 2013 75 5
  • The HER3/ErbB3 receptor: A promising target in cancer drug therapy
    C. Desbois-Mouthon
    Gastroentérologie Clinique et Biologique 2010 34 4-5
  • Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives
    Tae-You Kim, Sae-Won Han, Yung-Jue Bang
    Expert Review of Molecular Diagnostics 2007 7 6
  • Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds
    YU HUANG, YU CHEN, QIN MEI, YUAN CHEN, SHIYING YU, SHU XIA
    Oncology Reports 2013 29 6
  • Early Pharmacodynamic Assessment Using 18F-Fluorodeoxyglucose Positron-Emission Tomography on Molecular Targeted Therapy and Cytotoxic Chemotherapy for Clinical Outcome Prediction
    Masaki Kanazu, Kaoru Maruyama, Masahiko Ando, Kazuhiro Asami, Mari Ishii, Kazutaka Uehira, Shojiro Minomo, Yoshinobu Matsuda, Tomoya Kawaguchi, Shinji Atagi, Yoji Ogawa, Yoko Kusunoki, Minoru Takada, Akihito Kubo
    Clinical Lung Cancer 2014 15 3
  • Growth Stimulation of Non–Small Cell Lung Cancer Cell Lines by Antibody against Epidermal Growth Factor Receptor Promoting Formation of ErbB2/ErbB3 Heterodimers
    Mari Maegawa, Kenji Takeuchi, Eishi Funakoshi, Katsumi Kawasaki, Kazuto Nishio, Nobuyoshi Shimizu, Fumiaki Ito
    Molecular Cancer Research 2007 5 4
  • Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
    Hua Yang, Rong Wang, Shunli Peng, Longhua Chen, Qi Li, Wei Wang
    Oncotarget 2016 7 13
  • Ongoing First-Line Studies of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Select Patient Populations
    Pasi A. Jänne
    Seminars in Oncology 2005 32
  • Discovery of fluoroquinolone derivatives as potent, selective inhibitors of PI3Kγ
    Shao Sha, Hong-Wei Han, Fei Gao, Tian-Bao Liu, Zhen Li, Chi Xu, Wei-Qing Zhong, Hai-Liang Zhu
    MedChemComm 2015 6 11
  • ErbB3 mRNA Expression Correlated with Specific Clinicopathologic Features of Japanese Lung Cancers
    Osamu Kawano, Hidefumi Sasaki, Katsuhiko Endo, Eriko Suzuki, Hiroshi Haneda, Haruhiro Yukiue, Yoshihiro Kobayashi, Motoki Yano, Yoshitaka Fujii
    Journal of Surgical Research 2008 146 1
  • P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer
    Venkatasubbaiah A Venkatesha, Asavari Joshi, Magesh Venkataraman, Vinay Sonawane, Dimple Bhatia, Prashant Tannu, Julie Bose, Sarika Choudhari, Ankita Srivastava, Prashant Pandey, Vaibhavi J Lad, Ramachandra Sangana, Tausif Ahmed, Anagha Damre, Vijaykumar Deore, Bichismita Sahu, Sanjay Kumar, Somesh Sharma, Veena R Agarwal
    Molecular Cancer 2014 13 1
  • Phase I, dose-escalating study of elisidepsin (Irvalec®), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors
    Sanjay Goel, Santiago Viteri, Teresa Morán, Cinthya Coronado, Jorge Luis Iglesias Dios, Bernardo Miguel-Lillo, Eva M. Fernández-García, Rafael Rosell
    Investigational New Drugs 2016 34 1
  • Targeted Interference with Signal Transduction Events
    Nancy E. Hynes
    2007 172
  • The Role of Cetuximab in the Management of Non–Small-Cell Lung Cancer
    Taofeek K. Owonikoko, Shi-Yong Sun, Suresh S. Ramalingam
    Clinical Lung Cancer 2009 10 4
  • The function of human epidermal growth factor receptor-3 and its role in tumors (Review)
    QIN LI, ZHENYAN YUAN, BANGWEI CAO
    Oncology Reports 2013 30 6
  • Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer
    Wei Yang, Gary N. Schwartz, Jonathan D. Marotti, Vivian Chen, Nicole A. Traphagen, Jiang Gui, Todd W. Miller
    Oncotarget 2018 9 10
  • Sensitization of EGFR Wild-Type Non–Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib
    Judith Raimbourg, Marie-Pierre Joalland, Mathilde Cabart, Ludmilla de Plater, Fanny Bouquet, Ariel Savina, Didier Decaudin, Jaafar Bennouna, François M. Vallette, Lisenn Lalier
    Molecular Cancer Therapeutics 2017 16 8
  • Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC
    Jian Huang, Xiuwen Lan, Ting Wang, Hailing Lu, Mengru Cao, Shi Yan, Yue Cui, Dexin Jia, Li Cai, Ying Xing
    Oncogene 2020 39 8
  • Cell Free EGFR mRNA Expression and Implications for Survival and Metastasis in Non-Small Cell Lung Cancer Cases
    Mirza Masroor, Rashid Mir, Jamsheed Javid, Y Prasant, A Imtiyaz, Z Mariyam, Anant Mohan, PC Ray, Alpana Saxena
    Asian Pacific Journal of Cancer Prevention 2015 16 15
  • Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model
    Petra Martin, Erin Stewart, Nhu-An Pham, Celine Mascaux, Devang Panchal, Ming Li, Lucia Kim, Shingo Sakashita, Dennis Wang, Jenna Sykes, Thomas Friess, Frances A. Shepherd, Geoffrey Liu, Ming-Sound Tsao
    Clinical Lung Cancer 2016 17 5
  • Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line
    Nele Van Der Steen, Alessandro Leonetti, Kaylee Keller, Henk Dekker, Niccola Funel, Filip Lardon, Rob Ruijtenbeek, Marcello Tiseo, Christian Rolfo, Patrick Pauwels, Godefridus J. Peters, Elisa Giovannetti
    Biochemical Pharmacology 2019 166
  • Emerging therapies for colorectal cancer
    Aram F Hezel, David P Ryan
    Expert Opinion on Investigational Drugs 2007 16 6
  • Epidermal growth factor receptor pathway inhibitors
    Jose Baselga
    Update on Cancer Therapeutics 2006 1 3
  • Gefitinib for Epidermal Growth Factor Receptor Mutant Lung Cancers: Searching for a Weapon of Mass Destruction
    Pasi A. Jänne
    Journal of Clinical Oncology 2006 24 21
  • Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer
    Boyka Markova, Patricia S. Hähnel, Stefan Kasper, Stephan Herbertz, Martin Schuler, Frank Breitenbuecher
    Journal of Cancer Research and Clinical Oncology 2012 138 4
  • Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
    Guo-dong Cao, Ke Chen, Bo Chen, Mao-ming Xiong
    BMC Cancer 2017 17 1
  • Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells
    LIN WANG, ZHI-XIA ZHU, WEN-YING ZHANG, WEI-MIN ZHANG
    Experimental and Therapeutic Medicine 2011 2 5
  • Signaling Control by Epidermal Growth Factor Receptor and MET: Rationale for Cotargeting Strategies in Lung Cancer
    Eric B. Haura, Matthew A. Smith
    Journal of Clinical Oncology 2013 31 32
  • Vandetanib for the treatment of lung cancer
    Caleb T Chu, Yvonne H Sada, Edward S Kim
    Expert Opinion on Investigational Drugs 2012 21 8
  • HER3 expression is enhanced during progression of lung adenocarcinoma withoutEGFRmutation from stage 0 to IA1
    Toru Kumagai, Yasuhiko Tomita, Shin-ichi Nakatsuka, Madoka Kimura, Kei Kunimasa, Takako Inoue, Motohiro Tamiya, Kazumi Nishino, Yoshiyuki Susaki, Takashi Kusu, Toshiteru Tokunaga, Jiro Okami, Masahiko Higashiyama, Fumio Imamura
    Thoracic Cancer 2018 9 4
  • Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas
    Bénédicte Rysman, François Mouawad, Abigaëlle Gros, Amélie Lansiaux, Dominique Chevalier, Samuel Meignan, Patrick Ha
    Head & Neck 2016 38 S1
  • Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells
    Ping Li, Artour Torossian, Qing Zhang, Wen-cai Xu, Shen Fu
    Medical Oncology 2012 29 5
  • Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies
    Alexandra Eyzaguirre, Elizabeth Buck, Kenneth K. Iwata, John D. Haley, Mark R. Miglarese
    Targeted Oncology 2008 3 4
  • Surrogate Predictive Biomarkers for Response to Anti-EGFR Agents: State of the Art and Challenges
    F. Cappuzzo, L. Toschi, G. Finocchiaro, C. Ligorio, A. Santoro
    The International Journal of Biological Markers 2007 22 1_suppl4
  • siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells
    Heng-Heng Yuan, Ying-Nan Yang, Jian-Hua Zhou, Yan-Jing Li, Li-Ying Wang, Jun-Wei Qin, Tao Liu, Zhen-Zhen Li, Qing-Xin Zhou, Xiao-Li Wei, Ting-Ting Zhang, Peng Huang, Wen-Jie Zhang, Lei Liu, Xiao-Xue Du, Yu Han
    Oncotarget 2017 8 32
  • Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells
    Xin Li, Juan Pang, Wenwen Xue, Yixuan Wang, Tian Tian, Ahmed Elgehama, Xuefeng Wu, Xudong Wu, Yang Sun, Hongxia Qiu, Yan Shen, Qiang Xu
    Toxicology and Applied Pharmacology 2018 360
  • It’s all in for the HER family in tumorigenesis
    Major Kenneth Lee IV, Anupama Sharma, Brian J Czerniecki
    Expert Review of Vaccines 2010 9 1
  • Mechanisms of resistance to ErbB-targeted cancer therapeutics
    Qiang Wang, Mark I. Greene
    Journal of Clinical Investigation 2008
  • Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism
    Lingaku Lee, Irene Ramos-Alvarez, Terry W. Moody, Samuel A. Mantey, Robert T. Jensen
    Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2020 1867 4
  • Reduced expression of CYLD promotes cell survival and inflammation in gefitinib‐treated NSCLC PC‐9 cells: Targeting CYLD may be beneficial for acquired resistance to gefitinib therapy
    Yuan Yuan, Liu Liu, Yi Wang, Shangquan Liu
    Cell Biology International 2020 44 9
  • Theme: Oncology - Molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates
    Mai Yamauchi, Noriko Gotoh
    Biomarkers in Medicine 2009 3 2
  • Systems analysis of protein signatures predicting cetuximab responses in KRAS , NRAS , BRAF and PIK3CA wild‐type patient‐derived xenograft models of metastatic colorectal cancer
    Andreas U. Lindner, Steven Carberry, Naser Monsefi, Ana Barat, Manuela Salvucci, Robert O'Byrne, Eugenia R. Zanella, Mattia Cremona, Bryan T. Hennessy, Andrea Bertotti, Livio Trusolino, Jochen H. M. Prehn
    International Journal of Cancer 2020 147 10
  • Anti‑tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations
    Yusuke Ogoshi, Kazuhiko Shien, Takahiro Yoshioka, Hidejiro Torigoe, Hiroki Sato, Masakiyo Sakaguchi, Shuta Tomida, Kei Namba, Eisuke Kurihara, Yuta Takahashi, Ken Suzawa, Hiromasa Yamamoto, Junichi Soh, Shinichi Toyooka
    Oncology Letters 2019
  • EGFR Signaling Networks in Cancer Therapy
    Haley L. Bennett, Tilman Brummer, Paul Timpson, Kate I. Patterson, Roger J. Daly
    2008
  • Macromolecular Anticancer Therapeutics
    Michele Milella, Ludovica Ciuffreda, Emilio Bria
    2010
  • Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer
    Surya K. Tripathi, Kamal Pandey, Kannan R. R. Rengasamy, Bijesh K. Biswal
    Medicinal Research Reviews 2020 40 6
  • Targeted Therapies
    Alexis B. Cortot, Pasi A. Jänne
    2011
  • The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads
    Valentina Boni, Manish R. Sharma, Amita Patnaik
    American Society of Clinical Oncology Educational Book 2020 40
  • Thérapie anti-EGFR: vers un ciblage « à la carte » du carcinome hépatocellulaire
    Lætitia Fartoux, Christèle Desbois-Mouthon, Raoul Poupon, Olivier Rosmorduc
    Gastroentérologie Clinique et Biologique 2006 30 10
  • Antitumour immunity regulated by aberrant ERBB family signalling
    Shogo Kumagai, Shohei Koyama, Hiroyoshi Nishikawa
    Nature Reviews Cancer 2021
  • Cancer Cell Signaling
    Brent Rexer, Siprachanh Chanthaphaychith, Kimberly Dahlman, Carlos Arteaga
    2014
  • Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma
    ZHUN WANG, QIAN-BO HAN, JIA-LEI GU, XIN-MIN YU, XIAO-JIANG SUN, QING-REN LIN, JUN FANG, YUE-ZHEN WANG, YA-PING XU, WEI-MIN MAO
    Oncology Letters 2015 9 1
  • Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations
    Rafael Rosell, Enriqueta Felip, Noemí Reguart, Teresa Moran
    Future Oncology 2005 1 3
  • Current Research into Head and Neck Cancer Molecular Targeted Therapy and Human Papilloma Virus Infection in Head and Neck Squamous Cell Carcinoma
    Satoshi Fukuda, Hiromitsu Hatakeyama
    Practica Oto-Rhino-Laryngologica 2012 105 3
  • EGFR Signaling Networks in Cancer Therapy
    Stuart Thomson, John D. Haley, Robert Yauch
    2008
  • EGFR Signaling Networks in Cancer Therapy
    Elizabeth Buck, Alexandra Eyzaguirre, Kenneth K. Iwata
    2008
  • EGFR Signaling Networks in Cancer Therapy
    David A. Eberhard
    2008
  • Exploring the radiosensitizing potential of AZD8931: a pilot study on the human LoVo colorectal cancer cell line
    Cinzia Antognelli, Isabella Palumbo, Simonetta Piattoni, Monica Calzuola, Beatrice Del Papa, Vincenzo N. Talesa, Cynthia Aristei
    International Journal of Radiation Biology 2020 96 11
  • IASLC Thoracic Oncology
    Aaron S. Mansfield, Grace K. Dy, Mjung-Ju Ahn, Alex A. Adjei
    2018
  • Insulin-like Growth Factors and Cancer
    Joan M. Carboni, Mark Wittman, Fei Huang
    2012
  • Lung Cancer
    Erminia Massarelli
    2014
  • Lung Cancer
    Rafal Dziadziuszko, Barbara Szostakiewicz, Fred R. Hirsch
    2007
  • Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy
    Elisa Zucca, Emmanuele Crespan, Federica Bertoletti, Miroslava Kissova, Giovanni Maga
    2013 1
  • Molecular Targeted Therapy of Head and Neck Cancer: Promising Molecular Targets of Post-Epidermal Growth Factor Receptor Era
    Jae Won Chang, Chul-Ho Kim
    Korean Journal of Otorhinolaryngology-Head and Neck Surgery 2014 57 9
  • New insights into ErbB3 function and therapeutic targeting in cancer
    Umbreen Hafeez, Adam C Parslow, Hui K Gan, Andrew M Scott
    Expert Review of Anticancer Therapy 2020 20 12
  • PI3K/MEK pathway-targeted therapy in non-small cell lung carcinoma
    Ali Ahmad, Ali Jafar, Yaqoub Alshatti, Udo Schumacher
    Cogent Medicine 2015 2 1
  • PTPRKsuppresses progression and chemo‐resistance of colon cancer cells via direct inhibition of pro‐oncogenicCD133
    Masashi Matsushita, Yusuke Mori, Kyosuke Uchiumi, Takehiro Ogata, Mizuyo Nakamura, Hiroyuki Yoda, Hiroaki Soda, Nobuhiro Takiguchi, Yoshihiro Nabeya, Osamu Shimozato, Toshinori Ozaki
    FEBS Open Bio 2019 9 5
  • Plasma DNA as a “liquid biopsy” incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer
    Mary D. Chamberlin, Jason D. Wells, Kevin Shee, Jennifer R. Bean, Jonathan D. Marotti, Wendy A. Wells, Heidi W. Trask, Fred W. Kolling, Ananta Bhatt, Peter A. Kaufman, Gary N. Schwartz, John M. Gemery, Nancy J. McNulty, Michael J. Tsapakos, Richard J. Barth, Bradley A. Arrick, Jiang Gui, Todd W. Miller
    Breast Cancer Research and Treatment 2020 182 3
  • Renal Cell Carcinoma
    Sarathi Kalra, Eric Jonasch
    2015
  • Renal Cell Carcinoma
    Eric Jonasch, Cheryl Lyn Walker
    2009
  • Systems Biomedicine
    Qiang Yu, Edison T. Liu
    2010
  • The path of Iressa resistance
    Michael J. Haas
    Science-Business eXchange 2008 1 24
  • The role of ErbB3 N-glycan in dimer formation: Implications for transforming activity
    Shunichi Yokoe
    Trends in Glycoscience and Glycotechnology 2008 20 114
  • Therapeutic Kinase Inhibitors
    Yixuan Gong, William Pao
    2011 355
  • Tumortherapie im Spannungsfeld von Pharmakoökonomie und Innovation*
    U. Gatzemeier, F. Griesinger, R.M. Huber, M. Thomas
    Oncology Research and Treatment 2007 30 1

Article usage

Article usage: February 2005 to January 2021

AbstractFullPdf
Feb 2005980208
Mar 2005739335614
Apr 200551357282
May 200540284187
Jun 200529184126
Jul 20053114997
Aug 200539146103
Sep 200525135105
Oct 20052012993
Nov 2005259976
Dec 2005259467
Total 2005112219121958
Jan 20061610579
Feb 20062910556
Mar 20061814177
Apr 20061810465
May 20062210179
Jun 2006198064
Jul 2006139362
Aug 2006207152
Sep 2006254245
Oct 2006477256
Nov 2006396452
Dec 2006244736
Total 20062901025723
Jan 2007318875
Feb 2007136752
Mar 2007334741
Apr 2007426661
May 2007559566
Jun 2007277568
Jul 2007225244
Aug 2007225252
Sep 2007255357
Oct 2007345258
Nov 2007164545
Dec 2007163954
Total 2007336731673
Jan 2008205151
Feb 2008203850
Mar 2008425559
Apr 2008354850
May 2008267954
Jun 2008306453
Jul 2008792946
Aug 2008983647
Sep 20081062546
Oct 2008643050
Nov 20081144053
Dec 2008602733
Total 2008694522592
Jan 2009743039
Feb 2009472227
Mar 2009354834
Apr 2009284117
May 2009454130
Jun 2009384134
Jul 2009335143
Aug 2009256236
Sep 2009376641
Oct 2009513945
Nov 2009544943
Dec 2009544152
Total 2009521531441
Jan 2010454730
Feb 2010516851
Mar 2010326643
Apr 2010644033
May 2010406044
Jun 2010383532
Jul 2010403044
Aug 2010483934
Sep 2010624456
Oct 2010423133
Nov 2010453932
Dec 2010352028
Total 2010542519460
Jan 2011283332
Feb 2011522726
Mar 2011293428
Apr 2011414134
May 2011433441
Jun 2011372228
Jul 2011593136
Aug 2011642632
Sep 2011393733
Oct 2011513929
Nov 2011435337
Dec 2011323028
Total 2011518407384
Jan 2012293429
Feb 2012333728
Mar 2012364540
Apr 2012405248
May 2012442731
Jun 2012353821
Jul 2012323726
Aug 2012181516
Sep 2012363531
Oct 2012402837
Nov 2012332534
Dec 2012342218
Total 2012410395359
Jan 2013272734
Feb 2013363124
Mar 2013382428
Apr 2013381834
May 2013322032
Jun 2013322727
Jul 2013543030
Aug 2013282328
Sep 2013272715
Oct 2013293920
Nov 2013251719
Dec 2013332315
Total 2013399306306
Jan 2014373321
Feb 2014342312
Mar 2014221912
Apr 2014583127
May 2014403221
Jun 2014511917
Jul 2014432119
Aug 2014292516
Sep 2014331524
Oct 2014534731
Nov 2014392726
Dec 2014473820
Total 2014486330246
Jan 2015412726
Feb 2015432617
Mar 2015371769
Apr 2015403133
May 2015241413
Jun 2015301925
Jul 2015202218
Aug 2015141830
Sep 2015741829
Oct 2015392426
Nov 2015171230
Dec 2015311323
Total 2015410241339
Jan 2016261626
Feb 2016212325
Mar 2016282116
Apr 2016162618
May 2016192819
Jun 2016251114
Jul 2016362425
Aug 2016381513
Sep 2016521220
Oct 2016361217
Nov 2016442614
Dec 201637159
Total 2016378229216
Jan 2017442524
Feb 2017141813
Mar 2017612924
Apr 20172478
May 2017481915
Jun 2017222513
Jul 2017261917
Aug 2017303725
Sep 2017221314
Oct 2017321922
Nov 2017332014
Dec 20172220810
Total 2017378439199
Jan 2018493010
Feb 2018413119
Mar 2018414419
Apr 2018454215
May 2018242413
Jun 2018322810
Jul 2018393716
Aug 201860619
Sep 2018585214
Oct 201893415
Nov 201876918
Dec 201883716
Total 2018413489174
Jan 20195299
Feb 20190237
Mar 2019125420
Apr 201955720
May 2019133613
Jun 201973911
Jul 2019104722
Aug 201973524
Sep 2019814414
Oct 2019420311
Nov 2019116510
Dec 201925312
Total 201984785173
Jan 202064311
Feb 202014448
Mar 202051911
Apr 20208157
May 20201297
Jun 202072114
Jul 20202248
Aug 2020163319
Sep 202074712
Oct 2020112619
Nov 202092522
Dec 2020134218
Total 202099368156
Jan 202161710
Total 202161710
Total708692467409
PreviousNext
Back to top
Article Alerts
Email Article

Thank you for your interest in spreading the word on PNAS.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
(Your Name) has sent you a message from PNAS
(Your Name) thought you would like to see the PNAS web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
Jeffrey A. Engelman, Pasi A. Jänne, Craig Mermel, Joseph Pearlberg, Toru Mukohara, Christina Fleet, Karen Cichowski, Bruce E. Johnson, Lewis C. Cantley
Proceedings of the National Academy of Sciences Mar 2005, 102 (10) 3788-3793; DOI: 10.1073/pnas.0409773102

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
Jeffrey A. Engelman, Pasi A. Jänne, Craig Mermel, Joseph Pearlberg, Toru Mukohara, Christina Fleet, Karen Cichowski, Bruce E. Johnson, Lewis C. Cantley
Proceedings of the National Academy of Sciences Mar 2005, 102 (10) 3788-3793; DOI: 10.1073/pnas.0409773102
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Mendeley logo Mendeley
Proceedings of the National Academy of Sciences of the United States of America: 102 (10)
Table of Contents

Submit

Sign up for Article Alerts

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & SI
  • Info & Metrics
  • PDF

You May Also be Interested in

Abstract depiction of a guitar and musical note
Science & Culture: At the nexus of music and medicine, some see disease treatments
Although the evidence is still limited, a growing body of research suggests music may have beneficial effects for diseases such as Parkinson’s.
Image credit: Shutterstock/agsandrew.
Scientist looking at an electronic tablet
Opinion: Standardizing gene product nomenclature—a call to action
Biomedical communities and journals need to standardize nomenclature of gene products to enhance accuracy in scientific and public communication.
Image credit: Shutterstock/greenbutterfly.
One red and one yellow modeled protein structures
Journal Club: Study reveals evolutionary origins of fold-switching protein
Shapeshifting designs could have wide-ranging pharmaceutical and biomedical applications in coming years.
Image credit: Acacia Dishman/Medical College of Wisconsin.
White and blue bird
Hazards of ozone pollution to birds
Amanda Rodewald, Ivan Rudik, and Catherine Kling talk about the hazards of ozone pollution to birds.
Listen
Past PodcastsSubscribe
Goats standing in a pin
Transplantation of sperm-producing stem cells
CRISPR-Cas9 gene editing can improve the effectiveness of spermatogonial stem cell transplantation in mice and livestock, a study finds.
Image credit: Jon M. Oatley.

Similar Articles

Site Logo
Powered by HighWire
  • Submit Manuscript
  • Twitter
  • Facebook
  • RSS Feeds
  • Email Alerts

Articles

  • Current Issue
  • Latest Articles
  • Archive

PNAS Portals

  • Anthropology
  • Chemistry
  • Classics
  • Front Matter
  • Physics
  • Sustainability Science
  • Teaching Resources

Information

  • Authors
  • Editorial Board
  • Reviewers
  • Librarians
  • Press
  • Site Map
  • PNAS Updates

Feedback    Privacy/Legal

Copyright © 2021 National Academy of Sciences. Online ISSN 1091-6490